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Abstract 
Nature has evolved elegant strategies to temporally and spatially control protein 
activity, including the synthesis of subunits that require assembly for function, the 
incorporation of pro-domains that require cleavage for activation, and the formation of 
inhibitory and stimulatory networks that continually hold enzyme activity in balance. 
While nanomaterials have been developed with a myriad of functions for sensing or 
delivering biomolecules, the incorporation of Nature’s more sophisticated control 
strategies in nanoparticle systems has yet to be fully realized. Here, inspired by the 
biological motifs that control protein function, a series of nanoparticle coatings are 
developed that utilize bio-inspired strategies for temporal and spatial control, including 
emergent function through self-assembly, unveiling of latent properties in response to 
protease activation, and the integration of inhibitory and stimulatory protein interactions.  
Specifically: 
1) Protease removable polymer coatings are developed that veil and unveil 
complementary iron-oxide nanoparticles, leading to enhanced MRI contrast from 
protease-activated nanoparticle self-assembly. 
2) Prodomain nanoparticles are developed using removable coatings that veil 
nanoparticle-cell interactions, lengthen particle circulation times, increase tumor 
accumulation, and unveil nanoparticle surface domains upon cleavage by proteases in the 
tumor. 
3) Removable coatings are adapted to poly (β-amino ester) gene delivery vectors 
using electrostatically adsorbed peptide linkers, enabling localized gene delivery to 
cancer cells expressing tumor-associated proteases. 
4) Electrostatic coatings for gene delivery vectors are characterized and developed 
in vivo, leading to the identification of certain peptide-particle formulations that integrate 
stimulatory and inhibitory blood and cell surface interactions to achieve specific and 
effective organ-directed delivery.  
5) Materials used for gene delivery are applied to siRNAs, demonstrating the 
potential use of these coatings strategies for gene silencing applications. 
In order to achieve effective cancer therapy nanoparticles must overcome a series 
of sequential obstacles including undisrupted passage through the blood, accumulation in 
the tumor, shuttling across intracellular boundaries, and therapeutic delivery inside the 
cell. In this work we demonstrate how spatially and temporally controlled nanoparticle 
coatings effectively surmount these multiple barriers to improve imaging and therapy of 
tumors. 
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Chapter 1: Background and Significance 
1.1 Multifunctional Nanoparticles for Cancer Therapy 
Cancer cells evolve rapidly under incredible pressures, giving rise to macroscopic, 
microscopic and molecular characteristics, which limit the efficacy of treatments to 
inoperable tumors. In order for anti-cancer compounds to be effective they must 
overcome natural clearance mechanisms, localize to the tumor, and traverse extracellular 
and intracellular boundaries to arrive at their target and carry out their cytotoxic activity, 
all while having minimal effects on off-target tissues. Multifunctional nanoparticles 
provide promising solutions to many of these problems: they may exhibit unique 
pharmacokinetics including minimal renal filtration; they have high surface to volume 
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ratios enabling modification with various surface functional groups that home, 
internalize, or stabilize; and they may be constructed from a wide range of materials used 
to encapsulate or solubilize therapeutic agents for drug delivery or to provide unique 
optical, magnetic, and electrical properties for imaging and remote actuation[1]. The 
topology of a nanoparticle: core, coating, and surface ligands, makes it particularly 
amenable to modular design whereby features and moieties may be interchanged or 
combined. While many nanoparticle systems have been demonstrated for cancer therapy, 
including some clinically approved drug formulations and imaging agents[2-4], the 
incorporation of higher order functions into nanoparticles capable of addressing delivery 
barriers in a sequential and modular manner has been a significant challenge. 
 
 
Figure 1.1 Schematic depiction of a multifunctional nanoparticle. A hypothetical 
nanoparticle targets the tumor, senses and reports molecular signatures, and delivers a 
therapeutic in response to an external or biological trigger. Reprinted from Cancer Cell, 
Volume 2, E. Ruoslahti, 97-98, Copyright (2002), with permission from Elsevier. 
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Figure 1.1 schematically depicts a hypothetical multifunctional particle that has 
been engineered to include many features such as the ability to bind tumor endothelium, 
evade uptake by the reticuloendothelial system, encapsulate therapeutics that can be 
released on demand, sense molecular markers, and provide image contrast to signal the 
arrival at the tumor lesion. Some of these features, such as targeting, leverage biological 
machinery, while others are derived synthetically and enable external probing or 
manipulation that is otherwise unfeasible in biological systems. While this hypothetical 
model depicts the construction of a nanoparticle out of modular parts that seemingly 
operate exclusive from one other, more often the addition of modular functions on a 
nanoparticle effect properties such as surface potential, size, opsonin recognition, and 
target receptor avidity that invariably compromise the operation of other parts. For this 
reason strategies to seamlessly integrate multiple functions in a nanoparticle systems 
need to be investigated. 
 
1.1.1 Targeting  
The ability to physically target therapeutics to diseased cells while avoiding 
residual uptake in other tissues has long been a goal in cancer therapy[6-9]. The homing of 
stem cells to a tissue niche or the susceptibility of one cell over another to viral infection 
demonstrates that biomolecular recognition can be used to direct species to specific 
extracellular and intracellular sites. The microenvironment of the tumor, including cell-
surface markers, extracellular matrix, soluble factors, and proteases; as well as the 
tumor’s unique architecture and transport properties may be exploited for targeting[10-14].  
Both passive and active targeting has been utilized for nanoparticle delivery. 
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Passive targeting relies on the unique pharmacokinetics of nanoparticles including 
minimal renal clearance and enhanced permeability and retention (EPR) through porous 
angiogenic vessels in the tumor[15, 16]. Surface attachment of aliphatic polymers such as 
polyethylene (glycol) (PEG) on nanoparticles reduces adsorption by blood opsonins and 
minimizes uptake by mononuclear phagocytes in the liver, spleen, and lymph; 
lengthening nanoparticle circulation in the blood and accumulation in the tumor[17-19]. 
Active targeting relies on ligand-directed binding of nanoparticles to receptors expressed 
on the tumor endothelium or on cancer cells. Because nanoparticles circulating in the 
blood have direct access to vessel walls, binding of ligands to the tumor endothelium can 
occur immediately allowing nanoparticles to accumulate within tumor vessels. Particles 
equipped with ligands that bind to receptors expressed on cancer cells, must rely on the 
slower process of extravasation before gaining access to tumor epitopes. In this case 
nanoparticle accumulation is largely governed by the passive process of EPR, while 
tumor-specific epitopes function to overcome the final barrier of moving therapeutic 
particles from the extravascular space into cancer cells [20-24].  
Many candidate tumor markers have been described, some of which bind known 
ligands such as RGD-binding άVβ3 and άVβ5 integrins expressed on the surface of 
angiogenic blood vessels and folic-acid-binding receptors on the surface of cancer cells. 
These and others have been attached to the surface of various nanoparticle cores to 
deliver them to tumors[14, 25-27]. Monoclonal antibodies have also been used extensively 
for targeting. These can be isolated with high affinity for tumor markers and are useful 
for targeting receptors of unknown or low affinity ligands [28, 29]. Novel screens for 
discovering tumor homing ligands have been developed using phage and bacterial display 
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as well as libraries of aptamers, peptides, polymers, and small molecules[30, 31].  
While extracellular targeting to the tumor is sufficient for many modes of imaging 
and drug delivery, intracellular delivery of nanoparticles into the cytosol is essential for 
some applications. For example nanoparticles carrying membrane impermeable cargo 
that function in the cytosol, such as siRNA, antisense DNA, peptides, and other drugs, 
are minimally effective if delivered extracellularly or sequestered in the endosome[32]. 
Protein and peptide motifs capable of translocating nanoparticles into the cytoplasm have 
been borrowed from mechanisms of viral transfection. Two important classes of 
translocating domains include: poly cationic sequences and membrane fusion domains. 
Attaching the short poly-cationic sequence of HIV’s TAT protein, amino acid residues 
48-57, to a nanoparticle facilitates its adsorption on a cell surface and macropinocytotic 
escape into the cytosol[33, 34]. Similar results have been produced with highly charged 
poly arginines[35]. Use of this peptide for intracellular delivery in-vivo is limited by the 
adverse effect that poly-cationic sequences have on nanoparticle circulation time and 
RES uptake[36]. The amphiphilic domain derived from the N-terminus of the influenza 
protein hemagluttinin (HA2) is a membrane fusion peptide that destabilizes the endosome 
at low pH and facilitates viral escape into the cytosol[37]. Variations of this peptide with 
improved infectivity have also been synthesized[38]. Influenza-derived peptides have been 
used to enhance the delivery of liposomes as well as 100 nm poly-L-lysine particles.  
Another level of targeting can occur after translocation of nanoparticles into the 
cytosol to direct nanoparticles to specific sub-cellular structures. Using peptide 
localization sequences fluorescent quantum dots have been targeted to the nucleus and 
the mitochondria[39]. Several other localization sequences exist and could be used to 
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traffic nanoparticles to the endoplasmic reticulum, golgi apparatus, or peroxisomes. 
While work in this area has been focused on organelle labeling, the potential for 
delivering therapeutic nanoparticles to sub cellular structures is possible. Such 
nanoparticles could sense sub cellular aspects of disease or specifically intervene to more 
potently treat or eradicate cancer cells (i.e. free-radical mediated mitochondrial damage 
to induce apoptosis).  
While targeting of nanoparticles at the tumor, cell, cytosol, and organelle level 
have been elegantly demonstrated using a variety of molecular recognition domains, the 
incorporation of all of these parts into a single nanoparticle system remains a significant 
challenge. Attention must be paid to the compromising effect that individual components 
may have on nanoparticles size, surface potential, serum stability, circulation time, cell 
surface receptor avidity, cell membrane translocation, and diagnostic or therapeutic 
action. In this work we demonstrate how spatially and temporally controlled nanoparticle 
coatings can effectively direct the display of components to guide the accumulation, 
intracellular delivery, and nuclear targeting of diagnostic and therapeutic nanoparticles.  
 
1.1.2 Imaging  
Imaging cancer is crucial for guiding decisions about treatment and monitoring 
the efficacy of administered therapies. The use of nanoparticles for image contrast and 
enhancement has enabled improvements in cancer imaging by conventional modalities, 
such as magnetic resonance imaging (MRI) and ultrasound, and has established new 
techniques such as optical based imaging for cancer detection[36, 40, 41]. Targeted imaging 
agents that accumulate in otherwise undetectable lesions or that identify specific 
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biomarkers have the potential to improve detection, classification, and treatment of 
cancer with minimal invasiveness and reduced costs.  
 
Figure 1.2 Superparamagnetic nanoparticles provide T2 contrast in MRI. A) Proton spins 
deflect from and decay back to a main magnetic vector M0 with a time decay called T1. 
B) Proton spins become out of phase with each other leading to a reduction in MRI signal 
with a time decay called T2. T2 decay is enhanced by the presence of superparamangetic 
nanoparticles that disrupt the homogeneity of the local magnetic field. 
 
Superparamagnetic iron oxide nanoparticles have demonstrated clinical efficacy 
for detecting liver cancer and staging lymph node metastasis non-invasively with MRI[4, 
42] These particles detectably reduce T2 relaxation times by disrupting local magnetic 
field gradients causing water protons to spin out of phase with each other (Figure 1.2). 
Dextran coated iron-oxide nanoparticles administered intravenously get phagocytosed by 
normal macrophages of the liver and lymph and the failure of these tissues to darken after 
iron-oxide administration identifies invading cancer cells. Herceptin antibodies and folic 
acid attached to the surface of iron-oxide nanoparticles have been used to image their 
respective targets in tumors with MRI[43, 44] Other nanoparticle cores including 
dendrimers, micelles, and liposomes modified with paramagnetic gadolinium have also 
been used for tumor targeted MRI contrast[44-46].  
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Gold nanoshells offer an alternative to MRI probes by providing contrast for 
optical imaging [41]. These nanoparticles are constructed from a dielectric core (silicon) 
and a metallic conducting shell (gold). By varying the dimension of the core and shell, 
the plasmon resonance of these particles can be engineered to absorb or scatter 
wavelengths of light from UV to infrared. Particles that are tailored to scatter light in the 
near-infrared, where tissues have minimal absorbance, have been used to enhance 
imaging modalities such as reflectance confocal microscopy and optical coherence 
tomography (OCT) [47]. While the penetration of optical techniques does not approach 
that of CT or MRI, imaging features at depths of a few centimeters is possible. Gold 
colloids have also been used for optical contrast, but these lack the inherent tunability of 
nanoshells. The conjugation of optical contrast agents to antibodies has been used for the 
molecular imaging of the EGFR receptor on early cervical pre-cancers and for Her2+ 
breast carcinoma cells in mice [48, 49]. 
Fluorescent nanoparticles offer another useful tool to enhance optical detection. 
These probes are identified easily in microscopy and are useful for tracking the 
biodistribution of nanoparticles in experimental models. Fluorescent semiconductor 
nanocrystals, quantum dots, have been used to show ligand-mediated nanoparticle 
targeting to distinct features in the tumor[50]. Three different phage-display derived 
peptides were used to specifically target these nanocrystals to tumor blood vessels, tumor 
lymphatics, or lung endothelium. Quantum dots have a distinct advantage over 
conventional fluorophores because of their size-tunable excitation and emission profiles, 
narrow bandwidths, and high photo-stability[51, 52]. Using nanocrystals that fluoresce in 
the near infrared could extend their utility to clinical settings[53], though a key limitation 
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has been their potential toxicity because they are formulated from heavy metals[54]. One 
strategy to mitigate these toxicity concerns has been to develop coatings that stabilize 
these materials in serum, but are below the ~5nm size limit that allows them to be cleared 
renally[55, 56]. Alternative fluorescent nanoparticle probes have been developed including 
fluorescently tagged dendrimers and fluorophore-embedded silica nanoparticles [57-59]. As 
with plasmonic materials, the poor depth penetration of light in the tissue limits 
applications of fluorescent nanoparticle systems to within a few centimeters of access to 
an imaging device. 
Nanoparticle formulations that provide contrast for other imaging modalities 
including ultrasound and CT have been described. Perflourocarbon emulsion 
nanoparticles composed of lipid-encapsulated perfluorocarbon liquid, about 250nm 
diameter, are effective in giving echo contrast [60]. Air-entrapping liposomes formulated 
from freeze-drying techniques have also been developed to give ultrasound contrast[61, 62]. 
These agents can be used both to image passive accumulation in RES organs and 
lymphatics as well as angiogenesis. Bismuth sulfide nanoparticles can be used as contrast 
agents for CT imaging giving blood pool contrast similar to that of iodine, but at lower 
concentrations. These can also be used to image lymph nodes after phagocytic uptake[63]. 
As with other imaging modalities, the attachment of appropriate ligands to nanoparticle-
based CT and ultrasound contrast agents could be used for molecular imaging. 
While CT, Echo, MRI, and optical based contrast agents have been developed and 
their feasibility demonstrated in a variety of applications, key challenges for their 
widespread use in detection and classification of cancer remain. In particular the targeting 
of these agents in sufficient number to the tumor over other tissues has been an elusive 
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goal with the best methods delivering a relatively small percentage of the injected dose to 
the tumor. In the absence of active mechanisms to pump particles from the blood into the 
tumor against diffusion and pressure gradients, means of enhancing the signal of particles 
that have arrived in the tumor should be devised. In this work one such strategy is 
demonstrated through the design of protease-triggered self-assembling nanoparticles that 
acquire enhanced MRI contrast upon activation by proteases from cancer cells. Strategies 
such as this that control the spatial and temporal properties of nanoparticle imaging 
agents could enable earlier diagnosis and improved classification of cancer. 
 
1.1.3 Therapy 
The use of nanoparticulate drug carriers can address many critical challenges in 
drug delivery by improving drug solubility and stability, extending drug half-lives in the 
blood, reducing adverse effects in non-target organs, and concentrating drugs at the 
disease site[64]. Drugs may be dispersed in a matrix, encapsulated in a vesicle, dissolved 
in a hydrophobic core, or attached on the surface of a nanoparticle. Several nanoparticle 
based drug delivery systems including liposomes, polymeric nanoparticles, dendrimers, 
ceramic-based carriers, micelles, and others have been used to carry small molecule, 
peptide, and oligonucleotide therapeutic agents [21, 65]. Many promising anti-cancer drugs 
fail to make it to the clinic because of poor solubility or high collateral toxicity at 
therapeutic levels, thus motivating the need for these carriers in cancer therapy.   
Liposomes have been the most extensively utilized nanoparticle based carriers for 
delivering anti-cancer drugs. First described decades ago, these sub-micron sized carriers 
consist of amphiphilic lipids that assemble to form vesicles that can encapsulate drugs. 
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[66] Liposome-encapsulated doxorubicin is a clinically approved nanoparticle formulation 
used for chemotherapy [67]. The surface of this nanocarrier is PEGylated to reduce rapid 
uptake by phagocytic cells and extend the drug circulation time for better therapeutic 
efficacy. Several other liposome-encapsulated chemotherapeutic drugs have been 
described with many in clinical trials [68]. Active targeting of these liposomes through the 
attachment of antibodies and various ligands has also been demonstrated [29] [69]. Drug 
loaded liposomes with encapsulated or surface-functionalized gadolinium or fluorophores 
have been used to simultaneously image tumors during nanoparticle targeted drug 
delivery[70-72]. 
Biodegradable polymer nanocarriers have also been investigated as a means of 
encapsulating drugs and releasing them over time. Both poly (lactic-co-glycolic acid) 
(PLGA) and polylactic acid (PLA) nanoparticles have been formed that immobilize drugs 
dispersed in their matrix and release them upon degradation [21, 73]. Polymeric micelles 
consist of amphiphilic block copolymers that self assemble into a water-soluble 
nanoparticle with a hydrophobic core. These can be used to encapsulate water-insoluble 
drugs such as doxorubicin and adriamycin and targeted to tumors[74-76]. Polymersomes are 
another variation of polymer-based nanoparticulate vesicles that self-assemble from 
amphiphilic block copolymers [77]. These have been used to encapsulate doxorubicin and 
adriamycin with well-controlled release over several days[78, 79]. 
Yet another class of nanoparticle based drug carriers are dendrimers. These 
consist of a network of branching chemical bonds around an inner core. One of the more 
popular dendrimers, polyamidoamine dendrimers (PAMAMs), are non-immunogenic, 
water soluble, and posses terminal amine functional groups for conjugating a variety of 
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surface moieties [80]. Their inner core can been used to encapsulate anti-cancer drugs such 
as adriamycin and methotrexate[81]. Drugs may also be conjugated to the dendrimer 
surface along with ligands for targeting [82, 83]. A dendrimer functionalized with FITC, 
folic acid, and methotrexate has been synthesized to have imaging, targeting, and drug 
delivery capabilities [84]. The synthesis of these conjugates in a scalable and reproducible 
manner has been described for potential clinical applications[85]. 
Other nanoparticulate carriers including nanoemulsions, drug nanocrystals, and 
polyelectrolyte carriers have been developed. Nanoemulsions are formed by dissolving a 
drug in a lipid, cooling under high pressure, and homogenization to form solid 
nanoparticle lipid carriers at body temperature. Homogenization techniques can also be 
used to form crystalline nanosuspensions of drugs [64]. These formulations increase drug 
solubility and control release kinetics of the drug in the blood and at the tumor site. 
Polyelectrolyte carriers formed by the layer-by-layer absorption of polycationic and 
polyanionic moieties can be used to encapsulate therapeutic cargo particularly larger 
agents such as peptides and oligonucleotides [86]. Another multi-layer nanovector 
recently described achieves dual drug-release using a PLGA polymer core encapsulating 
doxorubicin and a PEG-lipid block-copolymer shell loaded with combrestatin[87]. The 
lipophilic anti-angiogenesis drug, combrestatin, intercalates in the nanoparticle 
membrane and releases rapidly upon association with tumor endothelial cells, while the 
slower releasing doxorubicin increases cytotoxic killing of tumor cells for a prolonged 
time after the vasculature shuts down.  
Despite these cleaver therapeutic strategies, to date only two nanoparticle 
formulations have been clinically approved for cancer treatment, liposomal doxorubicin 
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and abraxane. Both of these rely on the basic mechanism of passive delivery to 
accumulate chemotherapeutic drugs in the tumor and neither of these completely 
eliminates side effects from drug accumulation in non-tumor tissues. The field of 
nanoparticle therapeutics is still far from achieving the goal of tumor specific delivery 
with no off-target delivery. A key focus of this work is to develop strategies that control 
nanoparticle function in time and space, eliminating the need to completely block 
residual uptake of nanoparticles outside the tumor. By mimicking strategies that nature 
has evolved to tightly regulate protein function, we develop coatings that integrate higher 
order control function into nanoparticles making them more effective targeting, imaging 
and therapeutic agents. 
 
1.1.3.1 Gene Therapy 
 
Gene therapy offers a promising means to halt the progression of cancer on a genetic 
level. Through improved understanding of the molecular basis of cancer and a detailed 
cataloguing of genes from the genome projects of various species, a variety of strategies have 
been devised for mediating individual and collateral cancer cell death using gene delivery. 
Examples include the delivery of suicide genes that restore the function of apoptotic enzymes 
such as p53[88, 89], gene-directed enzyme prodrug therapy that converts inert molecules to toxins 
only in the tumor[90], and DNA vaccines that direct the immune system to attack cancer cells[91]. 
While a variety of gene therapy strategies have been developed over the last several years with 
many entering clinical trials, the lack of safe, efficient and controllable methods for delivery 
continues to limit these approaches[32, 92, 93]. 
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Gene delivery methods can be classified broadly into two main categories: viral and non-
viral. Viruses have evolved elegant and highly efficient mechanisms to transfect cells in a specific 
and coordinated fashion. Viral vectors such as adenovirus, lentivirus, and herpes simplex virus 
may be manipulated to incorporate therapeutic genes and used to deliver these genes to tissues or 
cells of interest. While these constructs achieve very efficient gene delivery, safety is still a key 
limitation. Inflammatory reaction to an adenovirus vector has caused death in one patient and 
insertional mutagenesis, a process by which the insertion of the gene in the chromosome by a 
virus disrupts the expression of a tumor-suppressor or oncogene, has lead to malignancy in 
others[94-96]. There are also risks that viral vectors that have been rendered non-replicative could 
revert to or co-purify with replication-competent virions. Additionally, the cost and complexity of 
scaling up gene therapy for the clinical could limit the widespread use of this approach[32]. 
Non-viral methods have the potential to mitigate some of the safety and manufacturing 
concerns of viral vectors, albeit, to date, they lack the efficiency of viral vectors. Synthetic 
vectors are generally composed of cationic materials that condense anionic plasmid DNA into 
nanovectors. These materials may be comprised of cationic lipids, polymers, or both. While 
cationic lipids have been shown to transfect with relatively good efficiency, in vivo toxicity and 
lack of serum stability limit the effectiveness of these approaches[97]. Polymers offer an 
alternative system for engineering vectors that address barriers to gene therapy in a highly 
modular fashion. A variety of constructs can be designed employing chemistries containing 
DNA-binding moieties, serum stabilizing motifs, reducible bonds, targeting ligands, and other 
domains that assist in the packaging and delivery of DNA across intracellular and extracellular 
boundaries. A few examples of polymers used to condense and deliver DNA to cancer cells 
include polylysines [98], polyethylenimines (PEI) [99, 100], polyamidoamine (PAMAM) dendrimers, 
and cyclodextrin-containing polymers[101-103].  
While off-the-shelf DNA transfection reagents such as PEI and PAMAM have 
demonstrated gene delivery in vitro and in vivo, the accumulation of these polymers in cells has 
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undesirable cytotoxic effects. Recently a degradable class of polymers called poly(β-amino 
esters) was developed that efficiently condenses DNA at pH 5.0, but degrades at pH 7.4 into non-
cytotoxic components[104]. A library of 2,350 structurally unique poly(β-amino esters) was 
synthesized and characterized for toxicity and transfection efficacy using a high-throughput 
screening method[105]. The best performing candidates have shown great promise in vitro and in 
vivo and further modifications have yielded polymers that have significantly improved 
transfection efficiency over PEI with negligible toxicity[106, 107]. One of these candidates was used 
to delivery the suicide gene diphtheria toxin to cancer in the intraperitoneal space [108]. 
Still, poly (β-amino esters) and other DNA condensing polymer face formidable 
challenges for achieving efficient and controlled delivery to tumors, particularly those that must 
be accessed systemically. Serum stability is a critical limitation for many DNA polyplexes. 
Positively charged complexes aggregate in serum with the adsorption of albumin and other 
anionic serum proteins. The resulting aggregates can cause toxicity by embolizing particulates in 
the lung[109, 110]. Modification of nanovectors with hydrophilic polymers stabilize these polyplexes 
in serum and prevent inactivation by the adsorption of serum proteins[111, 112]. However, these 
hydrophilic coatings introduce an entropic penalty that also restricts nanovector-cell interactions 
preventing internalization and intracellular trafficking[113].  Borrowing from the elegant design 
nature has evolved for proteolytically removable pro-domains to temporally control the activity of 
proteins, in this work we develop a system of electrostatically adsorbed protease removable PEG 
coatings that veil gene vectors in serum, but are effectively removed by tumor-specific proteases 
to activate gene delivery to nearby cancer cells. 
Viruses have evolved elaborate strategies to achieve organ, tissue, or cell-specific 
targeting. However, polymer nanovectors are generally promiscuous in their attachment to and 
internalization into cells. Typically, cell specificity is only achieved when the surface potential of 
polymer nanovectors is made electroneutral, often resulting in a loss of transfection 
efficiency.[114]. Recently a poly-glutamic acid based electrostatic coating was developed that 
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tethered cRGD ligands to deliver vectors specifically to human umbilical vein endothelial cells 
(HUVECs)[115]. These electrostatic coatings could provide a means by which the biophysical 
properties of nanovectors may be tuned to alter their serum stability or change transport 
properties in vivo. Mirroring the example set forth by nature, in which the simultaneous action of 
agonistic and antagonistic processes are integrated to direct protein function, in this work we 
demonstrate the use of electrostatic coatings to fine tune the balance of serum protein adsorption, 
nanovector size, and cell attachment to achieve highly specific delivery to either the liver or the 
spleen and bone marrow. These formulations have the potential to target gene delivery to 
hepatocellular carcinomas of the liver or leukemias and metastases of the bone. 
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1.1.3.2 Therapeutic RNA Interference 
 
Figure 1.3 Mechanisms of RNA interference. A) Double stranded RNAs (dsRNAs) 21 
nucleotides in length with 2 nucleotide 3’ overhangs mediate RNA interference in 
mammalian cells. B) dsRNAs are cleaved by Dicer and loaded onto RISC, which 
subsequently degrades the sense strand leaving a complex of the ‘anti-sense’-strand with 
RISC to degrade complementary mRNA found in the cell. Permissions from PhilippN 
under the CC-BY-SA-2.5 license. 
 
RNA interference (RNAi) presents a fundamentally new way to treat diseases by 
altering the expression of previously ‘undruggable’ genes at the mRNA level. By 
applying our understanding of the genetic mechanisms that give rise to and sustain cancer, 
RNAi could enable the selective knockdown of categorized oncogenes or other supporting 
proteins to halt cancer progression[116].   This mechanism, first discovered in the nematode C. 
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Elegans and subsequently demonstrated in mammalian cells [117, 118], comprises two important 
pathways: the first utilizes double stranded perfectly matched short interfering RNAs (saran’s) ~ 
21 nucleotides in length (Figure 1.3) and the second involves imperfectly matched hairpin 
structures encoded in the genome that are processed into microRNA (miRNAs). 
In the siRNA pathway double stranded RNAs (dsRNAs) are processed into a complex that 
catalytically cleaves complementary mRNAs leading to a significant reduction in protein 
synthesis. Initially dsRNAs are cleaved by the RNAse III enzyme Dicer and incorporated into an 
Argonaute 2 (AGO2) and RNAi-induced silencing complex (RISC)[119-121]. If there is perfect 
complementary between the sense and antisense strand, AGO2 cleaves the sense strand and the 
remaining complex proceeds to bind and cleave any complementary mRNA in the cell. If there is 
imperfect complementarity between the sense and the antisense strand, as is the case with pre-
miRNA hairpins, then the RISC complex mediates the unwinding of the sense strand and the 
complex proceeds to bind mRNA to mediate translational repression and eventual degradation in 
cytoplasmic compartments called processing bodies (P-bodies)[122-124]. Because the RISC complex 
in the miRNA pathway only binds and represses a single mRNA, while RISC in the siRNA 
pathway mediates the cleavage of many mRNAs, the microRNA pathway is better suited to act as 
a fine-tuning regulator of gene expression. 
Because of their potent gene repression effects, most RNAi applications in 
development have focused on the use of siRNAs. Therapeutic siRNAs are typically 
synthesized as 21-nucleotide double stranded sequences with 2 nucleotide 3’ overhangs. 
Generally, siRNAs can be synthesized with very high target specificity minimizing off-
target effects, though special consideration must be paid to the off target silencing of 
genes with matching seed-sequences in the mRNA 3’ UTR regions[125]. Interferon 
responses must also be thoroughly investigated during the design of siRNA therapeutics. 
These have been shown to be elicited in plasmacytoid dendritic cells that are activated by 
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specific sequence motifs, by dsRNAs longer than 30 base pairs through kinase PKR 
activation in the cytosol, and by toll-like receptors (TLRs) that sense dsRNA and ssRNAs 
in the endosome[126-128]. 
Effective delivery is the key limitation to the use of therapeutic siRNAs in cancer 
and most other diseases. Double stranded RNAs are susceptible to rapid cleavage by 
extracellular RNAses and incapable of traversing the hydrophobic cell membrane. As a 
result most strategies for in vivo siRNA delivery rely on the use of cationic lipids or 
polymers to condense siRNA into complexes that are protected from DNAse degradation 
and carry siRNAs across the cell membrane and out of the endosome. Stable nucleic-acid 
lipid particles (SNALPs) encapsulating siRNAs have been used for liver delivery in mice 
and monkeys[129]. A dose of 2.5mg/Kg of siRNA knocked down ApoB mRNA by more 
than 90% with silencing lasting for 11 days. This formulation has also been used to treat 
Hepatitis B and Ebola virus infection of the liver in mouse models[130, 131]. Recently a 
library of structurally unique lipidic materials called lipidoids were screened to identify a 
lipoplex that was effective in knocking down both ApoB and Factor VII expression for 
over 2 weeks[132]. Like SNALPs, these materials are rapidly cleared by the RES making 
them good candidates for liver applications, but not well suited for systemic delivery to 
tumors. 
The use of polymers for complexing and delivering siRNAs offers a promising 
alternative to cationic liposomes. Cationic polymers may complex with anionic siRNAs 
to form nanoparticles in a similar manner as they do with DNA. These polymers are 
highly modular with changes in size, charge, cleavability, or functional domains enabling 
control over nanovector size, serum stability, target specificity, and endosomal escape. 
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Some polymers have shown the capacity to deliver siRNAs to tumors systemically 
including: chitosan-siRNA nanoparticles, atelocollagen-siRNA complexes, cyclodextrin-
containing polycation nanoparticles, and PEI-siRNA nanoparticles[133-138]. While some of 
these polymer formulations for siRNA delivery look promising in initial studies, 
strategies to improve their safety, efficiency, and controlled delivery are paramount for 
translation to the clinic. Borrowing from the biologically inspired electrostatic coatings 
that we develop for gene delivery vectors, in this work we apply similar coatings to 
siRNA nanovectors. We show that siRNAs complexed with the materials and coatings 
we use for DNA delivery provide effective gene knockdown in cancer cells. These 
polyplexes have the potential to achieve specific, effective and controlled gene 
knockdown in vivo.  
 
1.2 Spatial and Temporal Control Systems in Nature 
Nature has evolved elegant strategies to temporally and spatially control protein 
activity, including the synthesis of subunits that require assembly for function, the 
incorporation of pro-domains that require cleavage for activation, and the formation of 
inhibitory and stimulatory networks that continually hold enzyme activity in balance. 
Such strategies are ubiquitous in biological systems. Control of function through complex 
assembly is utilized in DNA replication, transcription & translation, proteasomal 
degradation, vesicle formation and function, transmembrane receptor communication and 
a myriad of other processes. The synthesis of latent enzymes with cleavable prodomains 
is utilized extensively during the packaging and shipment of proteins to their sites of 
action. Proteinase activated receptors (PAR) represent a notable form of activated protein 
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function. PARs are activated by serine protease-mediated cleavage of their N-terminal 
extracellular domains to unveil sites that signal transduction pathways within a variety of 
cells contributing to processes such as muscle growth, bone cell differentiation and 
proliferation, and the inflammatory response[139]. Controlled function by mechanisms that 
integrate inhibitory and stimulatory protein interactions is apparent in a variety of 
intracellular and extracellular systems quite notably in the phosphorylation and 
dephosphorylation by kinases and phosphatases to toggle proteins between on and off 
states.  
 
Figure 1.4 Schematic depiction of the coagulation cascade. A cascade of factors 
integrating stimulatory and inhibitory signals leads to the activation of thrombin through 
the removal of its prodomain, which in turn converts fibrinogen to fibrin, which self-
assembles into a clot to staunch blood flow. Permissions granted under the BY-NC-ND-
2.5 license. See http://creativecommons.org/licenses/by-nc-nd/2.5/.  
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The blood-clotting cascade, as depicted in Figure 1.4, represents a highly sophisticated 
system of temporal and spatial protein control that effectively illustrates mechanisms of: 
self-assembly, removable pro-domains, and integration of inhibitory and stimulatory 
protein interactions. This cascade consists of a group of zymogens (inactive enzyme 
precursors) termed coagulation factors, which circulate throughout blood plasma in latent 
states until consecutively activated to catalyze other reactions, ultimately leading to the 
formation of fibrin clots. The assembly of fibrin clots provides the emergent function of 
staunching blood flow in areas of vascular damage. While crucial for stopping blood loss, 
the unchecked production of clots could lead to a variety of debilitating conditions such 
as stroke or pulmonary emboli. Nature has embedded temporal and spatial control 
mechanisms to ensure that clotting is only initiated when needed. This is partially 
achieved by the structural inhibition of clotting factors by prodomains. Once activated, 
catalytic domains are released and enzymes in turn catalyze other activation reaction. The 
cascade culminates in thrombin’s conversion of fibrinogen into fibrin, which is then 
polymerized to form clots by FXIII. Thrombin activates a variety of other coagulation 
factors in a positive feedback loop that results in increased thrombin production, while 
also activating protein C, which operates in a negative feedback loop to inhibit the 
cascade. The design of positive and negative feedback loops in the system balance 
inhibitory and stimulatory protein interactions to restore normal blood homeostasis and 
prevent hyper and hypo-coagulative states. The system achieves remarkable precision 
enabling highly sensitive and specific control over clot function at times when it is 
needed. 
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In this work we draw upon similar bio-inspired strategies to develop nanoparticle 
coatings that exploit self-assembly, latency, and integration of agonistic and antagonistic 
inputs to achieve temporal and spatial control over nanoparticle function. We 
demonstrate that these designs enable improved imaging, targeting, and therapeutic 
delivery to tumors by nanomaterials. 
 
1.2.1 Self-Assembly 
 
Figure 1.5 The assembly of superparamagnetic nanoparticles enhances T2 contrast in 
MRI. A) Proton spins become out of phase with each other leading to a reduction in MRI 
signal with a time decay called T2. B) T2 decay is increased by the assembly of 
superparamangetic nanoparticles into clusters with enhanced magnetic dipoles that 
perturb the local magnetic field. 
 
Self-assembly of nanoparticles has been used for the sensitive detection of a variety 
of biological specimen in vitro. Highly sensitive detection of DNA and proteins has been 
demonstrated by the self-assembly of complementary gold nanoparticles[140]. The 
clustering of these nanoparticles generates a plasmon shift resulting in a detectable red 
shift in their peak absorbance. Sensitive biological detection has also been demonstrated 
by the assembly of superparamagnetic nanoparticles [141, 142]. The clustering of magnetic 
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nanoparticles increases the effect of each magnetic dipole on the diffusional dephasing of 
water molecules around it, giving rise to a T2 relaxivity that is greater than the effect of 
each of the particles on their own (Figure 1.5)[143-145]. In general these self-assembling 
systems employ complementary chemistries that are constitutively exposed and lack 
elements of temporal control that could broaden their applicability. In this work we 
develop a removable polymer coating that, when applied to complementary 
nanoparticles, enable them to exist in a ‘latent’ state until triggered by an enzyme 
activator to self-assemble. Conceptually, the assembly scheme bears resemblance to 
fibrin clot formation during blood coagulation. The design is an important step and proof 
of principle that higher order systems of nanoparticles may be engineered to precisely 
interact with biological systems to carry out useful functions such as imaging or therapy. 
 
1.2.2 Stimuli Responsive Nanoparticles 
 
Stimuli responsive nanoparticles and polymers that respond to oxygen, pH, 
enzymes or other microenvironmental cues in tumors have been developed for a variety 
of diagnostic and therapeutic applications[146]. Strategies for modifying nanoparticle 
properties in response to enzymatic activities have been designed which are catalyzed by 
proteases[147, 148], peroxidases[149], and kinases[150]. Among these, matrix 
metalloproteinases (MMPs) are especially promising targets for cancer therapy because 
of their specific role in cancer pathogenesis[151]. One of the most well studied MMP 
proteins is MMP-2, which is implicated in angiogenesis, invasiveness and metastasis and 
known to be upregulated in many cancers[152-156]. Fluorogenic probes have demonstrated 
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that MMP-2 is minimally active in blood serum and specifically expressed in certain 
tumor models, cleaving intravenously administered substrates on the order of hours in 
vivo[157]. Other proteases such as cathepsins, urokinase plasminogen activator, and 
thrombin have been implicated in tumor processes and are also promising targets for 
responsive nanoparticle systems[158, 159]. 
A few examples of protease activated chemotherapy and DNA delivering 
liposomes and lipoplexes have been described in the literature[160, 161]. In these systems 
poly (ethylene glycol), PEG, is attached via protease cleavable linkers to suppress the 
fusion of the lipoplex with the cell membrane and is removed in the tumor by proteases. 
While initial data indicates the in vivo feasibility of such an approach. Little has been 
done to explore the incorporation of removable PEG or polymer coatings in non-lipid 
based nanoparticles and the extent to which functional motifs such as small molecules, 
peptides, or proteins could be transiently veiled with a cleavable polymer coat. 
Furthermore, the effects of polymer length and density, the activation kinetics of the 
polymer coating by proteases, and the generalizability of a responsive polymer coating 
for veiling the activity of a variety of nanoparticle platforms has not been investigated. In 
this work we develop and characterize many parameters of removable polymer coatings 
in vitro and in vivo and establish this as a viable approach for spatially and temporally 
controlling the presentation of nanoparticle surface ligands in the tumor. Conceptually 
this work bears resemblance to the controlled conversion of pro-thrombin to its active 
form thrombin as sites of injury. We apply this strategy to polymer nanovectors 
mediating gene delivery and gene knockdown, demonstrating the potential for these 
coatings to improve specificity and control over gene therapy. 
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1.2.2.1 Steric Cloaking by Polymers 
 
Figure 1.6 Polymer density dependent effects on steric stabilization of surfaces. At low 
surface densities, polymers remain in a random coil configuration termed the mushroom 
regime. At higher densities, polymers align to form a tight impenetrable brush layer. 
 
A key component of the coating systems we develop in this work utilize the steric 
stabilization of hydrophilic polymers on a nanoparticle surface. Scaling theory has been 
used to describe how polymer coils attached at varying densities on a surface impart a 
repulsive force on an approaching surface[162, 163]. This is due to the entropic penalty of 
confining the mixing between polymer chains and solvent when two surfaces come into 
close apposition. The free energy per unit area between two polymer-coated surfaces can 
be written: 
 
W = kT/lg3 [ 8Lb/5 (2Lb/D)5/4 – 4D/7 (D/2Lb)3/4 ] 
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Where D is the distance between the surfaces, Lg is the distance between the grafting 
points of the polymer, and Lb is the extension length[164]. While this equation is derived 
for flat surfaces, it is a valid approximation as long as the range of separation is much 
smaller than the particle radii. At low surface coverage, large Lg, and sufficient extension 
length, large Lb, polymers are in a random-coil conformation termed the mushroom 
regime (Figure 1.6). Diffusion of smaller macromolecules to the particle surface is 
allowed, while the particle’s approach to other particles or surfaces is repelled. By 
designing removable coatings within this regime, a nanoparticle can not approach 
particles or cells within the distance over which intermolecular forces of surface ligands 
and receptors interact, while protease activators may still diffuse through the polymer 
layer to gain access to the particle surface and remove the coating.   
Steric stabilization has been a key mechanism for improving the circulation time 
and tumor accumulation of stealth nanoparticles[165]. The chain flexibility of PEG grafted 
on nanoparticles is thought to be critical in preventing the adsorptions of opsonins, which 
lead to rapid clearance of these particles from the blood[166]. Nanomaterials engrafted 
with PEG have been able to achieve half-lives on the order of 20 hours [165]. These have 
been shown to achieve extravascular accumulation equal to that of ligand targeted 
carriers, suggesting that blood residence time is the most important factor for improving 
extravascular accumulation of these nanovesicles[23]. Long-circulating nanoparticles 
accumulate in tumors by the enhanced permeability and retention effect, in which the 
porous tumor vasculature enables passage of particles from the high concentration in the 
blood to the low concentration in the tissue[15, 167, 168]. Once entrapped in the extravascular 
space, diffusion out of the tissue into the blood proceeds much slower. The protease 
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responsive polymer coatings demonstrated in this work exploit the advantages in 
circulation time and EPR that are gained with hydrophilic polymer coatings. Combined 
with the specificity gained by activated unveiling of therapeutic and diagnostic 
capabilities, this approach presents an important strategy for transiently veiling cationic 
or immunogenic domains that would otherwise compromise tumor accumulation. 
 
1.2.3 Integrating Inhibitory and Stimulatory Protein Interactions 
There are inherent tradeoffs when combining many functional groups on one 
nanoparticle. In many cases a limited number of attachment sites are available on the 
particle surface, making it difficult to couple several groups in sufficient concentration 
for each of them to function. Moreover, some groups may interact to sterically shield or 
alter the activity of one another when combined in close proximity. Multiple functional 
moieties on a nanoparticle may also reduce colloidal stability or adversely affect its in 
vivo pharmacokinetics. While nature has evolved mechanism to sequentially unveil 
functional motifs as with latent enzymes or self-assembled complexes, it has also 
approached this problem by designing domains that integrate inhibitory and stimulatory 
protein interactions to achieve multiple functions in time and space[85]. In this work we 
borrow elements of this design by developing an electrostatic coating system that tunes 
the size and surface potential of nanovectors to manipulate the adsorption of serum 
proteins and cell internalizing properties in ways that lead to remarkable organ specific 
gene delivery. 
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1.3 Goal and Aims 
The central goal of this work is to develop nanoparticle coatings that overcome 
barriers to cancer therapy by utilizing bio-inspired strategies for temporal and spatial 
control. Three strategies are investigated: namely, emergent function through self-
assembly, unveiling of latent properties in response to protease activation, and the 
integration of inhibitory and stimulatory protein interactions to achieve emergent 
function. 
Towards this end various properties of coating architecture including 1) polymer 
length, density, and charge 2) conjugation strategies 3) cleavable domains and 4) 
stoichiometric combinations of surface moieties are investigated. The fates of 
nanoparticles incorporating these coatings are tested using in vitro and in vivo cancer 
models and their diagnostic and therapeutic efficacy is confirmed. Specifically, the aims 
of this work are: 
 
Aim 1: Investigate the design parameters for protease responsive 
coatings that veil and unveil nanoparticle self-assembly (Chapter 2). 
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Figure 1.7 Schematic depiction of protease activated nanoparticle self-assembly. 
 
The emergence of function through self-assembly is an essential component to the 
spatial and temporal organization of all living things. Inspired by these processes, we 
develop a system of nanoparticles that self-assemble in response to proteolytic inputs 
yielding an emergent signal that can be utilized for cancer imaging. We optimize the 
length and density parameters of a coating of hydrophilic polymers to sterically prevent 
ligands on a nanoparticle surface from approaching the attractive intermolecular forces of 
receptors on a complementary nanoparticle. By tuning these parameters to allow protease 
enzymes to diffuse through the layer of hydrophilic polymers and by attaching these via 
cleavable peptides, we design this protective polymer to be protease sensitive. The 
resulting system of particles is stable and monodisperse in solution in its latent form, but 
rapidly self assembles upon protease-mediated removal of the polymer coat. We show 
that this activated assembly leads to enhanced MRI contrast and utilize this system to 
detect protease expression by cancer cells. 
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Aim 2: Analyze the fate of nanoparticles bearing protease removable 
coatings that veil bioactive domains in vitro and in vivo (Chapter 3). 
 
Figure 1.8 Schematic depiction of protease activated unveiling of polymer coatings on 
nanoparticles bearing cell-internalizing domains. 
 
Following the pattern nature has evolved for using latent domains to control the 
initiation of protein activity in time and place, we apply the protease removable polymer 
coatings developed in Aim 1 to nanoparticles bearing bioactive domains. We show that 
the principles governing the exclusion of particles bearing removable polymer coatings 
from interparticle binding also limit ligands on a nanoparticle surface from approaching 
the attractive intermolecular forces of receptors on a cell membrane. Nanoparticles 
modified with cationic cell penetrating peptides are coated with a protease removable 
polymer and the cell uptake before and after proteolytic cleavage is investigated. 
Removal of the coating by proteolytic activity restores the binding of exposed moieties 
on the nanoparticle surface to the cell membrane. Nanoparticles are systemically 
administered to xenograft animals to test the effect of the polymer coating on trafficking, 
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biodistribution, and activation. We find that polymer veiling improves blood circulation 
time and tumor accumulation of nanoparticles bearing veiled internalizing domains. Once 
in the tumor, the polymer is removed by interstitial proteases, exposing the bioactive 
ligands on the nanoparticle. 
 
Aim 3: Develop protease-responsive electrostatic coatings for 
polymer gene delivery nanovectors (Chapter 4). 
 
Figure 1.9 Schematic depiction of protease responsive gene delivery nanovectors. 
 
The synthesis of proteins in latent forms is necessary in biological systems to 
prevent detrimental effects by protein function prior to its arrival at the site of activity. 
Similar control strategies applied to cancer therapy could limit adverse drug actions in 
tissues outside of the tumor. In this aim we apply the protease removable polymer 
coatings in Aims 1 & 2 to gene delivery nanovectors. By synthesizing cleavable polymers 
that are electrostatically adsorbed to DNA-poly (β-amino ester) polyplexes, we transiently 
block the gene delivery function of these complexes, but show that it is restored when 
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activated by tumor-associated proteases. As demonstrated in Aim 2, such strategies can 
improve the circulation time and tumor accumulation of nanovectors and add target-
specificity to gene delivery by having nanovector function unveiled in the tumor. 
 
Aim 4: Design electrostatic peptide coatings that integrate 
stimulatory and inhibitory protein interactions to achieve spatial control of 
gene delivery in vivo (Chapter 5). 
 
Figure 1.10 Schematic depiction of organ specific gene delivery through simply tuned 
electrostatic coatings that modulate nanovector-serum and cell interactions. 
 
The integration of inhibitory and stimulatory protein interactions is utilized for 
spatial and temporal control in many biological systems. In the design of polymer gene 
delivery vectors multiple inhibitory and stimulatory biological interactions influence 
nanovector function. The cationic domains of polymers are essential for condensing DNA 
and binding cell membranes to assist in internalization and transfection. However, these 
same cationic domains mediate an inhibitory effect on delivery function when injected in 
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the blood. The interactions of anionic serum proteins erythrocytes with cationic domains 
can form complexes with reduced function or toxicity as aggregates embolize to the lung. 
In this work we develop a technique for manipulating these inhibitory and stimulatory 
interactions to achieve organs specific targeting. By varying the density and charge of 
electrostatically adsorbed peptide coating we tune the surface potential of nanovectors to 
attenuate the adsorption of serum proteins and achieve a specific size and surface 
potential that is either suited for delivery to the liver or to the marrow and spleen. The 
organ specific targeting that is achieved with this simple coating formulation could be 
used to target malignant lesions in these organs including hepatocellular carcinoma, 
leukemias, and bone metastases. 
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Chapter 2: Protease Activated Nanoparticle Self-
Assembly 
2.1 Introduction 
Nature has evolved elegant strategies to temporally and spatially control the initiation 
of protein activity, including the synthesis of subunits that self-assemble to form a 
functional unit and the synthesis of proteins with pro-domains that require cleavage for 
activation. Nanomaterials that exploit bio-inspired self-assembling motifs have been used 
for sensitive detection of DNA[1, 2], proteins[3, 4], viruses[5], and pH changes[6] in vitro. In 
general these systems employ complementary chemistries that are constitutively exposed 
and lack elements of temporal control that could broaden their applicability. Here, 
inspired by the biological motif of initiating assembly by enzymatic removal of inhibitors, 
we demonstrate with peptide-polymer chemistry that inorganic nanoparticles may be 
functionalized to exist in a ‘latent’ state until triggered by a protease to self-assemble.  
We inhibit the binding of biotin and neutravidin coated superparamagnetic Fe3O4 
nanoparticles with polyethylene-glycol (PEG) polymers that may be proteolytically 
removed to initiate assembly by matrix metalloproteinase-2 (MMP-2), a protease 
correlated with cancer invasion, angiogenesis, and metastasis[7-9]. We demonstrate that 
MMP-2 initiated assembly amplifies the transverse (T2) relaxation of nanoparticle 
solutions in magnetic resonance imaging (MRI), enables magnetic manipulation with 
external fields, and allows MRI detection of tumor-derived cells that produce the 
protease.   In the future, this general approach may enable site-selective immobilization 
and enhanced image contrast in regions of tumor invasion in vivo. 
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Figure 2.1 Proteolytic Actuation of Self-Assembly Schematic. Neutravidin- and biotin- 
functionalized superparamagnetic iron-oxide nanoparticles are inhibited by the 
attachment of PEG chains that are anchored by MMP-2-cleavable peptide substrates 
(GPLGVRGC). Upon proteolytic removal of PEG via cleavage of the peptides, biotin and 
neutravidin particles self-assemble into nanoassemblies with enhanced magnetic 
susceptibility, T2 magnetic resonance relaxation, and lowered diffusivity. 
 
2.2 Results and Discussion 
The synthesis of proteolytically-actuated, self-assembling nanoparticles involves 
modifying them to be self-complementary, but rendered latent by protease cleavable 
elements (Figure 2.1). Briefly, 50nm dextran-coated Fe3O4 nanoparticles, sized by 
analytical ultracentrifugation (Micromod, Germany), are modified with either biotin or 
neutravidin (Pierce, Rockford, IL) to generate two populations of particles. When 
combined in solution, these particles self-assemble through highly stable biotin-
neutravidin interactions. To allow enzymatic control of particle assembly, the 
nanoparticle surfaces of both populations are modified with the MMP-2 peptide substrate, 
GPLGVRGC[10], which serves as an anchor for linear PEG chains.  
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Figure 2.2 Changes in light scattering of nanoparticles over time with MMP-2 [11 
µg/ml] (hollow) or without MMP-2 (solid) shows PEG length influence on particle 
aggregation kinetics. 
 
PEG is a highly mobile, hydrophilic polymer with a large sphere of hydration that 
has been widely used to deter adsorption of proteins or cells on surfaces and to extend 
therapeutic circulation times in vivo [11, 12].  We hypothesized that linear PEGs of 
appropriate lengths would inhibit association of 50 nm nanoparticles but still allow 
MMP-2 proteases (< 9 nm[13]) to cleave peptide linkers. To explore this idea we 
conjugated varying molecular weight PEGs (2, 5, 10, and 20 kDa) to biotin and 
neutravidin particles via MMP-2-cleavable linkers and tested their ability to assemble 
with and without MMP-2. The rate and extent of assembly was measured by monitoring 
changes in the solution extinction at 600nm (Figure 2.2). 
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Figure 2.3 Difference between the change in extinction of particles with and without 
MMP-2 after 3 hours reveals optimal PEG chain length of 10 kDa. 
 
Assembly of PEG-coated biotin and neutravidin particles without MMP-2 was 
found to be inversely related to PEG molecular weight with almost complete inhibition of 
particle assembly at lengths of 10 kDa or higher.  Nanoparticles incubated with MMP-2 
also aggregated at a rate inversely related to PEG chain length, likely due to a similar 
steric repulsion of MMP-2. Comparing the change in extinction of particles incubated 
with MMP-2 versus those without at 3 hours, the 5 kDa and 10 kDa PEGs allow the 
highest MMP-2-catalyzed assembly enhancement (Figure 2.3). However, because the 5 
kDa PEG cannot completely inhibit particle interaction in their latent state, 10 kDa was 
chosen as the optimum surface modification.  
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Figure 2.4 Characterization of protease activated assembly. A) Nanoparticles with 
specific MMP-2 substrate aggregate in the presence of MMP-2 [11 µg/ml] whereas 
particles with scrambled peptide do not.  B) Atomic Force Micrographs of particle 
solutions in C confirm aggregation of particles in the presence of MMP-2.  Scale bars are 
500nm. 
 
To further verify that the particle assembly was due to the sequence-specific 
release of PEG by MMP-2, a scrambled linker with low cleavage-specificity by MMP-2, 
GPVGLRGC[14], was generated and conjugated to particles. The nanoparticles with the 
scrambled peptide exhibit markedly decreased assembly compared to the specific peptide 
sequence (Figure 2.4). At 3 hours following MMP-2 addition, assemblies of 
nanoparticles with specific MMP-2 substrates, examined by atomic force microscopy 
(AFM), are as large as 0.5-1um, suggesting assembly of 10’s to 100’s of particles. The 
nanoparticles that are not incubated with MMP-2 remain disperse with diameter of ~75 
nm (Figure 2.4).  
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Figure 2.5 MMP-2 Triggered Self-Assembly Results In Detectable Changes In T2 
Relaxation Times. T2 maps generated by a 4.7T Bruker MRI shows detectable 
aggregation after 3 hours with the addition of 85, 170, 340, 680, and 1360 ng/ml MMP-2 
for nanoparticle concentrations of 32 pM, 10 pM, and 3.2 pM respectively.  
 
Nanoassemblies of iron oxide particles that form upon proteolytic-activation acquire 
emergent magnetic properties that may be remotely detected with MRI. The coordination 
of superparamagnetic Fe3O4 magnetic dipoles in assembled nanoparticles amplifies the 
diffusional dephasing of surrounding water molecules, causing shortening of T2 
relaxation times in MRI[15, 16]. We demonstrate that measurement of T2 changes allows 
sensitive, remote detection of protease-triggered assembly across a ten-fold variation in 
particle concentration (Figure 2.5). The concentrations used correspond to 0.7-7 mg 
Fe/kg of solution, spanning the working concentrations typically utilized for tumor and 
lymphatic targeting in vivo (2.6mg Fe/kg body weight)[17]. Nanoparticle solutions were 
incubated with varying concentrations of MMP-2 in a 384 well-plate and their T2 
relaxation times were mapped using a Carr-Purcell-Meiboom-Gill (CPMG) sequence on 
a 4.7T Bruker MRI. T2 shifts of greater than 150ms are observed by MMP-2 -triggered 
assembly in a 3.2 pM nanoparticle solution. For 10  pM and 32  pM concentrations, a T2 
shortening approximately 50% of the starting value is observed after incubation with 
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MMP-2. Nanoparticles at a 10  pM concentration were sensitive to at least 170 ng/ml [9.4 
U/ml] of MMP-2, which compares favorably with levels found in tumor tissue of 
MMP-2 expressing cancer cells [435 U/g MMP-2][14].   
 
Figure 2.6 T2 mapping of Fe3O4 nanoparticles incubated for 5 hrs over HT-1080 cells 
that secrete active MMP-2 in a complex medium.  Nanoparticle assembly amplifies T2 
relaxation over cancer cells relative to cells incubated with the MMP inhibitor Galardin at 
25 uM.  
 
Next, the utility of the protease-triggered nanoparticles was explored in complex 
biological specimens where non-specific protein adsorption is often problematic. 
Specifically, latent nanoparticles were incubated in cell culture medium above living 
human fibrosarcoma cells, HT-1080s, which constitutively express and activate MMP-
2[18, 19].  MMP-2 is a zinc binding protease with cleavage specificity for Type IV 
collagen, the principal constituent of basement membranes. Upregulation of MMP-2 
activity leads to invasive proliferation and metastases of cancer cells by breaking down 
tissue barriers[7, 8]. Nanoparticles (10 pM) were incubated over HT-1080 cells for 5 hours 
and T2 maps of media samples were generated with MRI. A substantial shortening in T2 
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was detected in the media over HT-1080 cells versus media over cells incubated with the 
broad-spectrum MMP inhibitor Galardin (Figure 2.6).  
 
Figure 2.7 Activated nanoparticles are drawn out of solution by a strong magnet (left) 
while inactive nanoparticles (right) are not.  
 
Triggered assembly of the nanoparticles can also be used to magnetically target 
nanoassemblies to cells. Similar to the T2 relaxivity enhancement in MRI, as the 
magnetic domains of coalesced nanoparticles coordinate to form an amplified cumulative 
dipole, they become more susceptible to long-range dipolar forces[20]. This phenomenon 
allows manipulation of the nanoassemblies with imposed magnetic fields, while isolated 
particles remain unaffected. Using a high-gradient permanent magnet, MMP-2 triggered 
assemblies of 1.5 nM nM iron oxide particles can be visually drawn out of solution, while 
non-activated particles remain disperse (Figure 2.7).  
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Figure 2.8 Nanoparticles activated by MMP-2 secreting tumor cells for 3 hrs are drawn 
out of solution onto cells by a magnetic field. Available neutravidins on aggregates are 
stained with biotin-quantum dots [Em: 605 nm] and imaged by epifluorescent 
microscopy. Assemblies are not targeted to cells if an MMP inhibitor is used. Scale bar 
represents 50 um. 
 
To demonstrate that this can be extended towards targeting particles onto cancer 
cells, HT-1080 cultures were placed over a strong permanent magnet and incubated with 
nanoparticles at a 150 pM concentration. After 3 hours, the media was removed and the 
cells were washed, fixed, and stained for aggregates using a biotinylated fluorescent 
probe. Bright fluorescent staining of particle assemblies is seen over HT-1080 cells, 
while weak diffuse staining, indicating little to no targeting, is seen over cells incubated 
with the inhibitor Galardin (Figure 2.8).  
 
2.3 Methods 
Synthesis of Nanoparticle Probes: Protease-triggered, self-assembling nanoparticles 
were synthesized using 50 nm amine-functionalized, dextran-coated iron-oxide 
nanoparticles (6.25 pmol/mg Fe), sized by analytical ultracentrifugation (Micromod 
(Germany)). All peptides were obtained at >90% purity (Synpep) and all reagents were 
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obtained from Sigma unless otherwise specified. A high gradient magnetic field filtration 
column was used between each conjugation (Miltenyi Biotec) and all conjugations were 
performed at room temperature unless stated.  Peptides were synthesized to sequentially 
contain a lysine (for the attachment of polyethylene glycol polymers), an MMP-2 
cleavage sequence (or scrambled version), and a terminal cysteine (for linkage onto 
amines in the dextran coat or lysines on neutravidin proteins). PBS designates 0.1 M Na 
Phosphate, 0.15  M NaCl buffer. For biotin probes, N-Succinimidyl 3-[2-pyridyldithio]-
propionamido (SPDP) (0.25 mg/ml) was reacted with particle amines (2.5 mg Fe) (1 ml 
PBS pH 7.2; 1 hr), where after cysteine-containing peptides [acetyl-KGPLGVRGC-X-
Biotin] (1 mg/ml) were added to displace pyridine-2-thione leaving groups (1 ml PBS 
with 10 mM EDTA pH 7.2; 12 hrs under N2; 4°C). Polyethylene glycol polymers with a 
terminal methoxy cap at one end and an opposing amine-reactive succimidyl α-
methylbutanoate (mPEG-SMB) (Nektar) (2.5 mM) were then attached to peptide lysines 
(1 ml PBS pH 7.2; 3 hrs). Neutravidin (Pierce) nanoparticles were formed by modifying 
particles (2.5 mg Fe) with biotinamidohexanoyl-6-amino-hexanoic acid N-hydroxy-
succinimide ester (0.5 mg/ml) (1 ml PBS pH 7.2; 1 hr) and then coating with a saturating 
concentration of neutravidin (850 µg neutravidin per 2.5 mg nanoparticles) (5 mls PBS 
pH 7.2; >3 hrs). The extinction of the solution at 600 nm was measured during incubation 
to ensure no aggregate formation. Additionally, neutravidin-coated particles were passed 
through a 0.1 um filter to confirm mono-dispersity. Using the same conditions described 
for biotin particle conjugations, peptides (KGPLGVRGC) were linked to available lysine 
amines on neutravidin-coated nanoparticles with SPDP, where after mPEG-SMB 
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polymers were linked to peptide lysines. Scrambled sequences used for control 
experiments contained GVRLGPG instead of GPLGVRG.  
 
Extinction, AFM, and Magnetic Field Migration Measurements: For all assembly 
experiments, equimolar ratios of particles were used. All extinction measurements were 
performed in duplicate in 384 well plates using a SpectraMax Plus spectrophotometer 
(Molecular Devices, Sunnyvale CA). Biotin and neutravidin probes (0.5 mg/ml; 0.1M 
HEPES 5 mM CaCl2 pH 7.2) were mixed at equal ratios and 0.5 µg of the recombinant 
catalytic domain of MMP-2 (Biomol,) (6 µl 50 mM Tris, 5 mM CaCl2, 0.005% Brij-35, 
pH 7.5) was added to 40 µl probe solution at time zero. For controls, 6 µl of buffer 
without MMP-2 was added. The same probe and MMP-2 concentrations were used for 
AFM and solution phase magnetic precipitation experiments. AFM measurements were 
performed using a multimode, Digital Instruments AFM (Santa Barbara CA) operating in 
tapping mode using FESP Tips (Veeco Nanoprobe TM, Santa Barbara CA). AFM 
reactions were incubated for 3 hours, diluted, and evaporated on freshly cleaved mica for 
analysis. In magnetic precipitation experiments, probe solutions were incubated with or 
without MMP-2 overnight and placed over a strong magnet for 2.5 minutes. 
 
MRI detection of self-assembly: MRI images were taken on a Bruker 4.7T magnet 
with a 7 cm bore. Biotin-peptide-PEG and neutravidin-peptide-PEG nanoparticles were 
mixed together and serially diluted in a 384 well plate. Serial dilutions of recombinant 
MMP-2 in 6ul of TRIS buffer were added to each well.  After 3 hours, a CPMG sequence 
of sixteen images with multiples of 10.45 ms echo times and a TR of 5000 ms were 
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acquired. T2 maps were obtained for each well by fitting images on a pixel-by-pixel basis 
to the equation y=M*exp(-TE/T2)  using MATLAB.  
 
Cell culture: HT-1080 human fibrosarcoma cells (ATCC) were cultured in 24-well 
plates using Minimum Essential Medium Eagle (Invitrogen) with 10% fetal bovine serum 
(Invitrogen) and 1% penicillin/streptomycin. For MRI experiments, the media was 
replaced with serum-free Dubelcco’s Modified Eagle Medium (DMEM - Invitrogen) 
containing 10 pM nanoparticle concentration.  The broad-spectrum MMP-2 inhibitor 
Galardin (Biomol) was added at a concentration of 25uM in control cultures. Samples of 
40 µl were taken at 5 hours for MRI imaging using the same procedures for T2 mapping 
described above.  For fluorescent labelling experiments, media was replaced with serum-
free DMEM containing 200 pM nanoparticle concentration and cells were placed over a 
strong magnet. After 3 hours, the media was removed and the cells fixed with 2% 
paraformaldehyde. The cells were permeabilized with 0.1% Triton-X in PBS and 
incubated with biotin quantum dots (EM: 605 nm - Quantum Dot Corp). Nuclear staining 
was performed by incubating with 0.001% Hoescht for 1 min. 
 
2.4 Conclusion 
To the best of our knowledge, this report represents the first demonstration of 
protease-triggered nanoparticle self-assembly.  This system differs from the reported use 
of enzymatic cleavage to prevent assembly [2, 21, 22]—rather it exploits proteolytic activity 
to construct multimeric assemblies with emergent properties. Previously, our laboratories 
have demonstrated that peptide-modified semiconductor quantum dots could precisely 
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target tumors in whole animals [23] and subcellular organelles in living cells [24]. This 
report extends the ability of nanoparticles not only to target sites of interest, but also to 
interact with the processes of disease by harnessing biological machinery to assemble 
nanomaterials with amplified properties. We show that polymeric protection can 
temporarily shield dissimilar complementary ligands, including both small molecules 
(biotin) and tetrameric proteins (neutravidin).   Accordingly, in contrast to recent reports 
of proteolytic activation of cell-penetrating peptides [19] and peroxidase-initiated 
nanoparticle assembly [4, 25], our approach can be considered entirely modular and thereby 
generalizable whereby key features (e.g. biochemical trigger, molecular recognition) may 
be altered without significant re-engineering.  Formulations with new functionalities 
could be easily developed by substituting the complementary binding pairs, cleavable 
substrates (e.g. glycans, lipids, oligonucleotides), or multivalent nanoparticle cores (e.g. 
gold, quantum dot, dendrimer) to extend the capabilities of existing modalities.  
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Chapter 3: Protease Activated Unveiling of Bioactive 
Nanoparticles 
3.1 Introduction 
Nanomaterials modified with biological recognition motifs acquire a myriad of 
functions that can be exploited for the diagnosis and treatment of cancer. Nevertheless, 
while bioactive domains can be used to target nanoparticles to cell receptors, shuttle them 
across cell membranes, and activate cell signaling, such modifications typically include 
cationic or hydrophobic regions that lead to rapid reticuloendothelial system (RES) 
clearance of particles from the blood, ultimately reducing particle accumulation in tumors 
[1, 2]. Further functionalization with hydrophilic polymers like poly (ethylene glycol) 
(PEG) can improve blood half-lives and tumor accumulation, but often at the expense of 
efficient ligand-mediated nanoparticle binding [3-5]. To address this tradeoff between 
improved biodistribution and optimal functionality on nanoparticles, we present a general 
strategy for reversibly veiling bioactive domains on nanoparticles using sterically 
protective polymers. We demonstrate that these materials effectively accumulate via the 
hyperpermeable vasculature of tumors and can be activated by cancer-secreted proteases 
to unveil hidden functional domains.  
Several cleavable polymers relying on reducible [6], pH-sensitive [7-15], and protease-
cleavable linkages [16, 17] have been described in the literature. While all of these systems 
enable rapid polymer release in the presence of appropriate physiological triggers, 
nanoparticles employing reducible or pH-sensitive linkages require transport through cell 
membranes or diffusion to acidic environments that may be hard to reach. Tumor-
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associated proteases, however, are expressed at the invasive front of tumors and at sites 
of angiogenesis, areas that are more easily accessed via passive particle accumulation, 
thus making nanoparticles sensitive to such enzymes excellent candidates for cancer 
therapy. Previously, we demonstrated that veiling particles with protease-cleavable 
polymers effectively suppresses the binding of complementary small molecules and 
larger proteins on nanoparticles [17, 18]. In this work we extend the utility of this technique 
by demonstrating that these coatings can be optimized to deter nanoparticle-cell 
interactions and to confer favorable circulation and accumulation properties in vivo. In 
contrast to the reported use of protease-cleavable PEGs to destabilize and fuse liposomes 
[19, 20] or the use of cleavable polyanionic peptides to electrostatically neutralize cationic 
domains [21, 22], this strategy exploits the entropic penalty imparted by hydrophilic 
polymers on approaching surfaces to veil and unveil the bioactivity of surface ligands. 
Consequently, this technique may be used to veil bioactive domains that need not be 
cationic or lipid-like, thereby enabling the regulation of functions besides fusion or 
internalization, such as cell binding or cell signaling. 
Using fluorescence imaging and MRI, we demonstrate that protease-removable 
polymer coatings effectively suppress cell uptake of nanoparticles bearing cell 
internalization domains, while proteolytic cleavage by MMP-2, a protease upregulated in 
angiogenesis, invasion, and metastasis [23-26], restores internalization function. In vivo, 
reversible polymer veiling greatly extends nanoparticle circulation in the blood over 
unveiled particles, and enhances tumor accumulation. We confirm that cleavable coatings 
on extravasated nanoparticles are removed in the tumor, thus establishing the potential of 
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this design for unveiling bioactive ligands in response to disease-associated triggers on a 
variety of nanoparticle platforms. 
 
3.2 Results and Discussion 
 
Figure 3.1 Schematic depiction of removable polymer coatings that veil and unveil 
bioactive ligands on a nanoparticle surface. A hydrophilic polymer (wavy-gray) linked 
via MMP cleavable substrates (jagged-yellow) veils the activity of a cell-internalizing 
domain (jagged-blue) on the surface of a magnetofluorescent nanoparticle. Veiled 
particles have extended circulation times that enable their passive accumulation in 
tumors. Extravasated particles are activated by MMP-2 in the microenvironment to unveil 
internalizing domains, which associate with the cell membrane and shuttle nanoparticles 
into cells. 
 
Figure 3.1 shows a schematic model of nanoparticles bearing protease-removable 
polymer coatings that veil the function of bioactive surface ligands. Two species, a cell 
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internalization domain and a removable hydrophilic polymer, consisting of a linear PEG 
tethered by an MMP-2 cleavable substrate, are conjugated onto the surface of a 
magnetofluorescent dextran-coated iron oxide nanoparticle. Prior to activation, the 
hydrophilic polymer prevents both RES-mediated clearance of the particles and systemic 
action of the bioactive ligand, in this case an internalizing domain.  
 
Figure 3.2 A library of nanoparticles with removable polymer coatings and a varying 
density of internalization ligands were screened for relative uptake by HT-1080 cancer 
cells before (veiled, blue) and after (unveiled, green) MMP cleavage. A density of 6 cell-
internalizing peptides per particle demonstrated optimal veiling and internalization. Error 
bars are standard deviations from three separate experiments. 
 
Previously we identified a removable polymer coating that was optimal for veiling 
and unveiling ligands mediating interparticle interactions [17]. We hypothesized that this 
approach could be extended to veil particle-cell interactions. To test this, we conjugated 
particles with the removable polymer coating and varying densities of cell internalization 
domains and then measured the uptake of veiled and protease-activated (unveiled) 
particles by HT-1080 cells using flow cytometry. Particles with lower domain densities 
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were taken up minimally by cells in both the veiled and unveiled state, while particles 
with higher domain densities were taken up by cells even with the intact polymer coating. 
An optimized particle design was selected based on a high level of internalization of 
unveiled particles and a low level of internalization of veiled particles, with the optimum 
ratio of internalization domains resulting in a 40-fold increase in cell accumulation 
(Figure 3.2).  
 
Figure 3.3 Size distribution intensity profiles by dynamic light scattering show 
unmodified particles with a Z-average of 63.4 nm and a PDI of 0.146. After modification 
with bioactive peptides and removable polymer, the particle size increases to a Z-average 
of 85.3 nm and a PDI of 0.08. Unveiled particles do not increase in size having a Z-
average size of 84.3 and a PDI of 0.316. 
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The optimum particle had, on average, 6 internalization domains per nanoparticle 
and 60 cleavable PEGs. Polymer coatings increased the hydrodynamic diameter of 
nanoparticles from 63 nm to 85 nm (Figure 3.3). Once activated by MMPs, unveiled 
particles did not aggregate, but remained colloidally stable in solution. 
 
Figure 3.4 Trafficking of unveiled nanoparticles by epifluorescence microscopy. MMP-
activated (unveiled) nanoparticles incubated over HT-1080 cells are imaged at 1, 3, and 5 
hrs. At 1 hr particles can be seen lining the cell membrane; over longer time points 
particles appear punctate in intracellular organelles that traffic to the nucleus. 
Internalization of veiled particles is not visible. Scale bar is 75 µm.  
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Figure 3.5 Unveiling of nanoparticles initiates cell-uptake in other cell lines. A) MMP-
activated (unveiled) nanoparticles internalize in brain (GLIO 1431), prostate (TRAMP), 
and breast (MDA-MB-435) cancer cell-culture models. Internalization of veiled 
nanoparticles is not visible (insert). Scale bar is 50 µm. B) Fold increase in mean 
internalization of unveiled over veiled nanoparticles after incubation for 5 hrs as 
measured by flow cytometry. Error bars are standard deviations of three separate 
experiments.  
 
To verify that internalization function is indeed restored after removal of the 
polymer coating, epifluorescence microscopy was used to monitor the trafficking of 
unveiled nanoparticles as they traveled from the cell membrane toward the nucleus 
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through intracellular organelles, a punctate pattern greatly reduced with veiled particles 
(Figure 3.4). Flow cytometry and microscopy studies using other cell lines confirmed 
that this effect is not specific to HT-1080 cells (Figure 3.5).  
 
Figure 3.6 Cells incubated with veiled and unveiled nanoparticles for 5 hrs were imaged 
by (left) a fluorescence scanner or (right) MRI, demonstrating the dual contrast properties 
of the nanoparticles and the correlated fluorescent and magnetic domain uptake of 
unveiled particles. 
 
The magnetic properties of the iron-oxide core particles used in these studies can 
also be used to confirm cell uptake of the particles with MRI. A T2 mapping sequence 
was used to detect T2 changes in cells that had been incubated with veiled and unveiled 
nanoparticles for 5 hours and imaged by a 4.7T MRI (Bruker). The internalization of 
nanocrystal cores leads to a measurable decrease in T2 signal which was significantly 
greater with unveiled particles and well correlated with signal changes detected in a 
planar fluorescence scan (Licor – Figure 3.6).  
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Figure 3.7 MMP-mediated removal of polymer coatings relieves TAMRA-iron 
quenching interactions, thereby enabling remote monitoring of protease activation. 
 
 
Figure 3.8 The Kcat/Km for peptide-polymer NPs (red) and free peptide (blue) was 
determined to be 8.42 and 26.7 µM-1hr-1 respectively by measuring the cleavage of the 
substrate by MMP-2 over time. Polymer veiling and immobilization of the cleavable 
peptide substrate reduces its associated MMP-2 Kcat/Km within a practical range, 3.2 fold. 
 
Given that the orientation of the cleavable substrate in this system is constrained 
between the nanoparticle and 10 kDa PEG, we sought to confirm that proteases could 
access the peptide backbone by comparing the catalytic efficiency (Kcat/Km) of MMP-2 
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for its substrate on the particle with the substrate free in solution. Since peptide-PEG 
domains were labeled with TAMRA in a position removed upon cleavage, activation of 
nanoparticles in solution and determination of the Kcat/Km can be monitored by the 
release of the TAMRA dye (Figures 3.7, 3.8)[18].  Using this approach, it was determined 
that proteases effectively accessed the peptide backbone for cleavage and that PEG 
shielding and particle immobilization resulted in only a 3.2-fold decrease in the Kcat/Km, a 
favorable reduction considering the order of magnitude decreases that have been reported 
with MMP-2 substrates on other immobilized polymers [27].   
 
Figure 3.9 Nanoparticles bearing cleavable (L-AA) polymer coatings have similar 
circulation times to non-cleavable (D-AA) controls, suggesting that the cleavable 
polymer remains intact in the blood. 
 
After completing these proof-of-principle experiments in vitro, we sought to 
characterize how the different surface properties of veiled and unveiled particles affect 
blood circulation times in vivo. To this end, we systemically administered to mice (via 
intravenous tail injections) veiled nanoparticles consisting of cleavable L-isomer amino 
acid peptide substrates (veiled L-AA), in addition to non-cleavable particles with D-
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isomer substrate analogs (veiled D-AA) and unveiled controls. The circulation time of 
cleavable particles was not significantly altered from that of non-cleavable controls, 
suggesting that the cleavable coating withstands degradation by proteases in the blood 
(Figure 3.9).  
 
Figure 3.10 Nanoparticles bearing MMP cleavable polymer coatings (veiled) have 
increased blood clearance times compared with particles that have had the coating 
removed by MMPs (unveiled). Error bars indicate standard deviation of three animals.  
 
This is supported by in vitro experiments that show that this MMP-responsive 
polymer is not activated by serum or serum enzymes [18]. Particles with unveiled bioactive 
domains had significantly reduced blood half-lives, clearing from the blood 
approximately 8 times faster than veiled particles, with more than 25% of PEG-veiled 
nanoparticles still in the blood at 4 hrs compared to unveiled particles that had 25% 
remaining after only 30 min (Figure 3.10).  
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Figure 3.11 Analysis of nanoparticle accumulation in the tumor at 48 hrs by FMT 
demonstrates similar accumulation of cleavable (L-AA) particles compared to non-
cleavable (D-AA) controls. The FMT analysis returned integer values, which were 
identical for all three animals injected with D-AA particles. 
 
 
Figure 3.12 Fluorescence molecular tomography (FMT) of regions of interest  (ROIs) 
selected around bilateral flank tumors from two representative animals shows intravenous 
injections of veiled nanoparticles yield greater accumulation in tumors after 48 hrs as 
compared to unveiled controls. 
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Figure 3.13 Analysis of nanoparticle accumulation in the tumor at 48 hrs by FMT 
demonstrates superior accumulation of veiled particles as compared to unveiled controls. 
Error bars represent standard deviation of three animals.  
 
Because the rate-limiting step of nanoparticle transport into the tumor is 
extravasation, size and circulation time are the most important factors governing their 
accumulation [28]. Empirically, 80-100 nm nanoparticles bearing targeting ligands that 
bind tumor cells in the extravascular space do not show increased accumulation over 
untargeted controls, though these strategies do improve therapeutic efficacy [29, 30]. In 
accordance with these results, the activation and subsequent internalization of cleavable 
particles should not enhance their accumulation over non-cleavable particles that remain 
in the extracellular space. Using fluorescence molecular tomography (FMT) we show that 
cleavable particles do not accumulate significantly more than non-cleavable controls in 
tumor regions of interest over 48 hours (Figure 3.11), but that they do accumulate 
significantly more than nanoparticles that have their bioactive domains unveiled (Figures 
3.12, 3.13).   
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Figure 3.14 Representative histological sections confirm the increased accumulation of 
veiled nanoparticles versus unveiled controls after 48 hrs; nanoparticles (green), blood 
vessels (red), nuclei (blue). Scale bar is 250 µm.  
 
Figure 3.15 T2 map of tumor and muscle ROIs after intravenous injection show 
enhanced contrast from veiled nanoparticles in the tumor versus normal tissue (muscle) at 
24 hrs post-injection. 
 
Histological analysis of tumors confirms increased accumulation of veiled particles 
as compared to unveiled particles and shows that particles have moved beyond vascular 
borders (Figure 3.14). Ultimately, these results translated to post-injection changes in T2 
relaxation times in tumors, but not normal muscle, by veiled nanoparticles administered 
to xenograft mice (Figure 3.15).  
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Figure 3.16 Recombinant MMP-2 (2.5 µg/ml) or collagenase (20 µg/ml) removes 
peptide-PEG and relieves TAMRA-iron quenching interactions enabling monitoring of 
protease activation. Incubation with the broad-spectrum inhibitor, Galardin (25 µM, 
Biomol), inhibits activation by both enzyme formulations. 
 
While these results generally exhibit the ability of veiled nanoparticles to passively 
accumulate in tumors and enable both fluorescent and magnetic-resonance tumor 
imaging, we aimed to demonstrate that cleavable particles are unveiled by endogenous 
MMP expression in tumor xenografts. MMP activation of cleavable (L-AA) particles by 
MMP-2 occurs rapidly with the majority of the polymer removed within an hour when 
incubated with enzyme in solution at a concentration even lower than what is estimated to 
be in xenograft tumors (63 µM vs. 1 mM)[19] (Figure 3.16).  
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Figure 3.17 Monitoring the release of TAMRA-iron quenching interactions shows that 
particles with cleavable L-isomer peptides (L-AA) are activated by MMPs, while 
particles with non-cleavable D-isomer peptides (D-AA) remain intact. 
 
 
Figure 3.18 Representative RGB merge of nanoparticles (green), removable polymer 
(red), and nuclei (blue) in tumor sections harvested 48 hours after injection shows a loss 
in signal from the removable polymer with cleavable peptides, but not non-cleavable 
controls. Scale bar is 250 µm.  
 
 84 
 
Figure 3.19 The percentage of particles colocalized with the removable polymer in tumor 
sections harvested 48 hours after injection is significantly reduced for the cleavable (L-
AA) particle. 
 
Monitoring the removal and subsequent dequenching of TAMRA fluorophores 
attached to the leaving peptide-PEG shows cleavable (L-AA) particles to be activated by 
MMPs, while non-cleavable (D-AA) particles are not (Figure 3.17). This removal of 
TAMRA-labeled peptide-PEG from the particle by MMP activation can be used as a 
sensor of protease unveiling in vivo. To measure this activation we performed 
colocalization analysis on fluorescent micrographs of peptide-PEG (TAMRA-labeled) 
and nanoparticles (VT-680-labeled) from histological sections of tumors harvested 48 
hours after injection (Figure 3.18). A pixel-by-pixel analysis of histological sections 
from tumors measuring the percentage of particles (green pixels) that colocalized with the 
polymer coating (red pixels) shows that the association of particles with their removable 
coating is reduced nearly 6-fold for cleavable particles, indicating the cleavable particle is 
in fact activated in the tumor (Figure 3.19). 
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3.3 Methods 
Unless otherwise stated all reagents were purchased from Sigma-Aldrich and all 
reactions were performed at room temperature.  
 
Synthesis of Nanoparticles: The nanoparticles used in these experiments were 
synthesized, cross-linked, aminated, and labeled with a near-infrared fluorophore 
(VivoTag 680) according to published protocols [31, 32]. Briefly, dextran-coated iron oxide 
nanoparticles were synthesized, purified, and subsequently cross-linked using 
epichlorohydrin. After exhaustive dialysis, particles were aminated by adding 1:5 v/v 
ammonium hydroxide (30%) and incubated on a shaker overnight. Aminated 
nanoparticles were subsequently purified from excess ammonia using a Sephadex G-50 
column and concentrated using a high-gradient magnetic-field filtration column (Miltenyi 
Biotec, Auburn, CA).  Amine-functionalized particles were labeled with the NHS ester 
NIR fluorochrome, VivoTag 680 (VisEn Medical, Woburn, MA), by adding 1:20 w/w 
and incubating on a shaker for one hour. Excess dye was removed by filtration on a 
Sephadex G-50 column. The particle molarity was determined by the viscosity/light 
scattering method [33].  
To conjugate species onto nanoparticles, surface amines were functionalized with 
SIA (N-succinimidyl iodoacetate) to make them thiol reactive. A FITC-labeled 
polyarginine cell internalizing peptide, NH2-RRRRGRRRRK(FITC)GC, and a TAMRA-
labeled protease-cleavable PEG, prepared by coupling the amine terminus of an MMP-2 
cleavable peptide substrate, NH2-GK(TAMRA)GPLGVRGC, to 10 kDa NHS-PEG[18], 
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were then linked to nanoparticles via thiol groups on the cysteine residues at the carboxyl 
termini. A more detailed protocol is available in the supplemental section. 
 
Peptide-PEG Synthesis: Peptides were synthesized in the MIT Biopolymers core to 
contain sequentially, an amino terminus for PEG attachment, a TAMRA-labeled lysine, 
an MMP-cleavage sequence, and a cysteine at the carboxyl terminus for particle 
attachment. The purity of the cleavable MMP2 substrate (NH2-G-K(TAMRA)-G-P-L-G-
V-R-G-C-CONH2) and the non-cleavable D amino acid analogue (NH2-G-K(TAMRA)-
G-dP-dL-G-dV-dR-G-C-CONH2) was verified with HPLC and mass spectrometry. 
Amine-reactive 10 kDa mPEG-SMB reagents (methoxy-polyethylene glycol- 
succinimidyl α methylbutanoate) were purchased from Nektar Therapeutics. Peptides 
were reacted with polymers in PBS + 0.005 M EDTA pH 7.2 at 500 µM and 400 µM, 
respectively, for >24 hours with shaking. Free peptide was removed by reducing with 0.1 
M TCEP and filtered using a G-50 Sephadex column. The reduced polymer was then 
quantified using fluorochrome extinction and added to nanoparticle preparations as 
described below.  
 
Ligand Attachment to Nanoparticles: The attachment of peptide-PEGs to 
nanoparticles was performed simultaneously with attachment of cell internalizing 
peptides (NH2-RRRRGRRRRK(FITC)GC, MIT Biopolymers). The internalizing peptide 
purity was verified by HPLC and mass spectrometry and its concentration was quantified 
using the molar extinction coefficient of FITC. Aminated nanoparticles (1.3 mg Fe/ml) 
were reacted with N-succinimidyl iodoacetate (11 mM) in 0.1 M HEPES 0.15 M NaCl pH 
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7.2 (HEPES buffer) for 3 hours and filtered using a G-50 Sephadex column into 
phosphate buffered saline + 0.005 M EDTA pH 7.2 (PBS-EDTA buffer). Purified 
nanoparticles (0.06 mg Fe/ml) were then combined with stock solutions of reduced 
peptide-PEG (60 µM) in PBS-EDTA buffer and internalizing peptide (serial dilutions of 
63 µM, 50.4 µM, 37.8 µM, 25.2 µM, 12.6 µM, & 0 µM) in 0.1% TFA at 1:3 and 1:0.1 
v/v respectively.  The stock concentration selected for the optimized particle was 25.2 
µM. The number of ligands per particle was determined spectrophotometrically using a 
pre-determined extinction coefficient for iron nanoparticles, FITC-labeled internalizing 
peptide, and TAMRA-labeled peptide PEG at 400 nm, 495 nm and 555 nm respectively. 
The optimized particle was determined to have 16 VT 680 dyes, 6 internalizing peptides, 
and 60 peptide-PEGs. 
 
Dynamic Light Scattering: DLS measurements for unmodified and veiled particles 
were performed in aqueous buffer with 0.1 M HEPES 0.15 M NaCl at 25ºC using a 
Malvern ZS90. Measurements on unveiled particles were performed in the solution used 
for activation after incubating with MMPs for 3 hours at room temperature.  
 
Microscopy: GLIO 1431 (obtained from Al Charest at Tuft’s University), TRAMP 
(obtained from Jianzhu Chen at M.I.T), and MDA-MB-435 (obtained form Erkki 
Ruoslahti at the Burnham Institute) were cultured in DMEM media with 10% FCS and 
1% P/S and grown to 80% confluency. Veiled and MMP-activated (unveiled) 
nanoparticles (100 µl at 0.1 mg/ml Fe) were added to 400 µl cell culture media with 25 
µM Galardin and incubated over cells for various times. For flow cytometry studies, 
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adherent cells were detached from the tissue culture plate with 0.25% trypsin, washed in 
PBS, and analyzed on a Becton Dickinson LSR II using a 633 nm excitation source and a 
690/40 band pass filter to detect VT-680 labeled nanoparticles in cells. Microscopy was 
conducted on live cells in glass bottom wells using a 100x objective and a cy5.5 filter 
cube (Chroma). 
 
Flow Cytometry: HT-1080 human fibrosarcoma cells (ATCC) were cultured in 24-
well plates and grown to 80% confluency using ATCC recommended media. Veiled and 
MMP pre-cleaved nanoparticles (100 µl at 0.1 mg/ml Fe) were added to 400 µl cell 
culture media with 25 µM Galardin and incubated over cells for 1 hour. Adherent cells 
were detached from the tissue culture plate with 0.25% trypsin, washed in PBS, and 
analyzed on a Beckman Dickson LSR II using a 633nm excitation source and a 690/40 
band pass filter to detect VT-680 labeled nanoparticles in cells. 
 
MMP Activation: Unless otherwise stated, pre-cleaved (unveiled) particles were 
prepared by incubating nanoparticles with 20 µg/ml collagenase (Clostridiopeptidase A) 
in  0.1 M HEPES 0.15 M NaCl pH 7.2 (HEPES buffer) with 5 mM CaCl2 for 3 hours at 
room temperature. Activation was monitored by the decrease of TAMRA quenching at an 
excitation of 515 nm and emission of 580 nm. Addition of 25 µM of the broad-spectrum 
MMP inhibitor (Galardin) prevented cleavage of peptide-PEGs as monitored by 
dequenching (Supplementary Figure 4). 
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Kcat/Km Determination: Cloaked nanoparticles (0.05 mg/ml Fe) coated with 2.9 µM 
of peptide-PEG substrate in HEPES buffer with 5mM CaCl2 were incubated with 
recombinant MMP-2 (0.724 µg/ml) at room temperature and monitored fluorometrically 
to assess activation. The Vmax of fluorescence release of particles at this concentration 
was linearly related to that of particles at concentrations ½ and 2-fold as much, indicating 
that the substrate concentration [S] was much less than the binding constant Km in this 
experimental setup. Activation experiments were quenched by the addition of 0.1 M 
EDTA at 1:9 v/v. Particles were ultracentrifuged and the supernatant collected to measure 
product formation. Similarly free peptide ([S]=15.45 µM) in HEPES buffer + 5 mM CaCl2 
was incubated with recombinant MMP-2 (0.3367 µg/ml). Activation was quenched by 
the addition of 0.1 M EDTA at a 1:9 v/v and cleavage was monitored using a 
fluorescamine assay. The Vmax of substrate cleavage during the first 30 min for substrate 
concentrations of 15.45 µM and 7.75 µM were linearly related confirming that the 
experiment was operating in a range of [S] much less than Km. The reaction was driven to 
completion over 24 hours and the change in fluorescamine signal at various time points 
was used to determine the substrate concentration. 
 
Multimodal Imaging in Agarose Wells: A 5% agarose solution in water was boiled 
and then cooled in a cell culture dish containing well molds from centrifuge tubes. Each 
well was filled with 8 million cells from a 40% confluent T-150 flask. HT-1080 cells in 
these flasks were incubated with nanoparticles (1 µg/ml Fe) in DMEM with serum media 
for various times. Particles were removed after incubation and cells were trypsinized, 
washed in PBS, fixed overnight in 50 µl of PBS with 4% paraformaldehyde, and 
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transferred to agarose wells for imaging. MRI images were taken on a Bruker 4.7T 
magnet, 7 cm core. A series of 32 images with multiples of 15 ms echo times and a TR of 
3000 ms were acquired. T2 maps were obtained for each well using the T2 fit map plug-
in in OsiriX imaging software. A fluorescence scan through the wells was acquired on an 
Odyssey Infrared System (Licor) using the 700-emission channel to detect VT-680 
labeled particles. 
 
Xenograft Animals:  Nude mice were injected s.c. bilaterally in the hind flank with 
2x106 HT-1080 cells. After 1-2 weeks animals were anaesthetized with isoflurane and 
injected through the tail vein with nanoparticles (4–10 mg/kg Fe). Animals were imaged 
before and 24 hrs after intravenous injection of nanoparticles (10 mg/Kg Fe) on a 4.7T 
Bruker magnet. A series of 16 images with multiples of 8.6 ms echo times and a TR of 
2133.3 ms was acquired. T2 maps were obtained for regions of interest using the T2 fit 
map plug-in in OsiriX. At 48 hours animals were imaged by a fluorescence molecular 
tomography (FMT) imaging system (Visen Medical). Quantitative analysis of relative 
nanoparticle uptake in tumors by FMT was assessed by selecting regions of interest 
around tumor masses 4-6 mm in diameter. Quantitative measurements on dye 
concentrations were normalized by the total injected dose in each animal to yield relative 
fluorescent units (RFUs). Blood half-lives were determined by the decrease in particle 
fluorescence (VT-680) of 25 µl blood samples withdrawn periodically into heparinized 
capillary tubes from the sub-orbital space. Withdrawn blood was diluted with 50 µl of 
PBS containing 10 mM EDTA, centrifuged for 1 minute at 1000 RPM to remove RBCs, 
and read on an NIR scanner (LICOR, 700 channel). Animals were euthanized by cervical 
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dislocation under anesthesia and tumors were harvested, embedded in OCT, and stored at 
-80°C for cryosectioning. Samples were cut into 5 µm sections using a cryotome and 
fixed in cold acetone for staining and imaging. 
 
Colocalization Analysis: Histological sections were labeled with an anti-TAMRA 
primary antibody (AbD Serotec) and an Alexa-750 secondary antibody (Invitrogen) to 
confirm the presence of TAMRA-labeled polymer on nanoparticles in the tumor tissue. 
Twelve image fields from three different tumor specimens were acquired for animals 
injected with cleavable (L-AA) and non-cleavable (D-AA) nanoparticles. To cancel the 
background signal from noise and non-specific antibody binding, the cumulative 
distribution of pixel intensity data from all analyzed fields was generated for VT-680 and 
TAMRA antibody channels, and a value determined from the inflection point was 
subtracted from all images. The number of non-zero pixels in the particle fluorescence 
channel that colocalized with non-zero signal from the TAMRA channel were counted 
and divided by the total number of particle pixels to obtain a percentage of colocalized 
particles for each image from 23 images.  
 
3.4 Conclusion 
The removal of the polymer in the tumor highlights a key feature of this system, the 
implicitly engineered spatial regulation of ligand function: particles remain in a 
functionally latent state in the vascular space (enabling increased circulation times and 
tissue accumulation) until they extravasate and are activated by cancer-associated 
proteases in the tumor microenvironment (enabling improved site-specific functionality). 
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In this paper we have built on previous work in which the entropic penalty of PEG 
coatings was used to veil and unveil ligands mediating particle-particle interactions by 
extending this strategy to veil and unveil ligands mediating particle-cell interactions. 
Additionally we have shown that removable polymer coatings confer favorable tumor 
targeting properties in vivo.  In the future, the incorporation of core particles carrying 
drug or nucleic acid cargo and bioactive domains mediating cell signaling or cell-specific 
binding in this strategy could provide a cytotoxic response to protease unveiling and 
ultimately lead to a multifunctional platform for improved imaging and therapy.  
 93 
 
3.5 References 
[1] S. M. Moghimi, A. C. Hunter, J. C. Murray, Pharmacological Reviews 2001, 53, 
283. 
[2] R. Weissleder, A. Bogdanov, E. A. Neuwelt, M. Papisov, Advanced Drug 
Delivery Reviews 1995, 16, 321. 
[3] S. Alexander, Journal De Physique 1977, 38, 983. 
[4] P. G. Degennes, Macromolecules 1980, 13, 1069. 
[5] G. Storm, S. O. Belliot, T. Daemen, D. D. Lasic, Advanced Drug Delivery 
Reviews 1995, 17, 31. 
[6] S. Zalipsky, M. Qazen, J. A. Walker, N. Mullah, Y. P. Quinn, S. K. Huang, 
Bioconjugate Chemistry 1999, 10, 703. 
[7] A. A. Kale, V. P. Torchilin, Journal of Liposome Research 2007, 17, 197. 
[8] E. S. Lee, K. Na, Y. H. Bae, Nano Letters 2005, 5, 325. 
[9] V. P. Torchilin, Advanced Drug Delivery Reviews 2006, 58, 1532. 
[10] J. A. Boomer, D. H. Thompson, Chemistry and Physics of Lipids 1999, 99, 145. 
[11] X. Guo, F. C. Szoka, Bioconjugate Chemistry 2001, 12, 291. 
[12] F. Kratz, U. Beyer, M. T. Schutte, Critical Reviews in Therapeutic Drug Carrier 
Systems 1999, 16, 245. 
[13] E. Roux, C. Passirani, S. Scheffold, J. P. Benoit, J. C. Leroux, Journal of 
Controlled Release 2004, 94, 447. 
[14] S. Simoes, J. N. Moreira, C. Fonseca, N. Duzgunes, M. C. P. de Lima, Advanced 
Drug Delivery Reviews 2004, 56, 947. 
[15] M. J. Turk, J. A. Reddy, J. A. Chmielewski, P. S. Low, Biochimica Et Biophysica 
Acta-Biomembranes 2002, 1559, 56. 
[16] C. Bremer, C. H. Tung, R. Weissleder, Nature Medicine 2001, 7, 743. 
[17] T. J. Harris, G. von Maltzahn, A. M. Derfus, E. Ruoslahti, S. N. Bhatia, 
Angewandte Chemie-International Edition 2006, 45, 3161. 
[18] G. von Maltzahn, T. J. Harris, J.-H. Park, D. H. Min, A. J. Schmidt, M. J. Sailor, 
S. N. Bhatia, Journal of the American Chemical Society 2007, 129, 6064. 
[19] H. Hatakeyama, H. Akita, K. Kogure, M. Oishi, Y. Nagasaki, Y. Kihira, M. Ueno, 
H. Kobayashi, H. Kikuchi, H. Harashima, Gene Therapy 2007, 14, 68. 
[20] J. X. Zhang, S. Zalipsky, N. Mullah, M. Pechar, T. M. Allen, Pharmacological 
Research 2004, 49, 185. 
[21] T. Jiang, E. S. Olson, Q. T. Nguyen, M. Roy, P. A. Jennings, R. Y. Tsien, 
Proceedings of the National Academy of Sciences of the United States of America 
2004, 101, 17867. 
[22] Y. Zhang, M. K. So, J. H. Rao, Nano Letters 2006, 6, 1988. 
[23] B. Davidson, I. Goldberg, J. Kopolovic, L. Lerner-Geva, W. H. Gotlieb, G. Ben-
Baruch, R. Reich, Gynecologic Oncology 1999, 73, 372. 
[24] J. M. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, G. Jackson, J. 
Harper, G. Tamvakopoulos, M. A. Moses, Proceedings of the National Academy 
of Sciences of the United States of America 2000, 97, 3884. 
 94 
[25] G. Giannelli, J. FalkMarzillier, O. Schiraldi, W. G. StetlerStevenson, V. Quaranta, 
Science 1997, 277, 225. 
[26] M. E. Stearns, M. Wang, Cancer Research 1993, 53, 878. 
[27] Y. Chau, F. E. Tan, R. Langer, Bioconjugate Chemistry 2004, 15, 931. 
[28] A. Gabizon, H. Shmeeda, A. T. Horowitz, S. Zalipsky, Advanced Drug Delivery 
Reviews 2004, 56, 1177. 
[29] D. W. Bartlett, H. Su, I. J. Hildebrandt, W. A. Weber, M. E. Davis, Proceedings 
of the National Academy of Sciences of the United States of America 2007, 104, 
15549. 
[30] D. B. Kirpotin, D. C. Drummond, Y. Shao, M. R. Shalaby, K. L. Hong, U. B. 
Nielsen, J. D. Marks, C. C. Benz, J. W. Park, Cancer Research 2006, 66, 6732. 
[31] L. Josephson, C. H. Tung, A. Moore, R. Weissleder, Bioconjugate Chemistry 
1999, 10, 186. 
[32] S. Palmacci, L. Josephson, U.S. Patent Vol. 5 1993, p. 176. 
[33] F. Reynolds, T. O'Loughlin, R. Weissleder, L. Josephson, Analytical Chemistry 
2005, 77, 814. 
 95 
Chapter 4: Tumor-responsive Electrostatic Coatings 
for Gene Delivery Nanovectors 
4.1 Introduction 
Gene therapy holds great promise for the treatment of cancer, but safe and effective 
delivery is still a key limitation to this approach. Non-viral gene delivery vectors have 
emerged as a promising technology for mitigating the safety concerns of viral vectors, but 
these generally suffer from reduced efficiency and lack of cell-specific targeting[1, 2]. 
Strategies to increase tumor accumulation or target gene delivery to cancer cells could 
improve efficiency and reduce off-target effects. Recently, we demonstrated a covalently 
tethered protease-responsive coating strategy for veiling nanovectors to improve their 
accumulation and direct the unveiling of their surface domains in the tumor[3]. Here we 
describe a strategy to engineer protease responsive coatings for cationic nanovectors 
using electrostatically adsorbed poly (glutamic acid) (poly-E) peptides that tether 
cleavable poly (ethylene glycols) (PEGs). We demonstrate that these coatings stabilize 
cationic nanovectors in serum and target gene delivery function to cancer cells upon 
activation by cancer-associated proteases. 
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4.2 Results and Discussion 
 
Figure 4.1 Synthesis of cleavable PEG peptide coatings. 
 
In previous work a strategy for applying cyclic RGD terminated poly-E peptides 
to cationic nanovectors improved the specificity of gene delivery to HUVEC cells[4]. 
Building upon this approach we synthesized a 16-mer poly-E peptide terminated in a 
cleavable motif, GPLGVRG, that is be sensitive to MMP-2, a protease upregulated in a 
variety of cancers and associated with processes of angiogenesis, invasion, and 
metastasis[5, 6]. The cleavable domain separates the poly-E chain from the amino 
terminus, to which we attach a 10 kDa poly (ethylene glycol) succinimidyl valerate 
(PEG-SVA) (Figure 4.1). Previously we identified 10kd PEG as an optimum length 
polymer for transiently veiling bioactive domains on a nanovector surface[7, 8]. The 
coupling of PEG to the poly-E peptide is carried out with a 10x molar excess of PEG-
SVA to peptide in phosphate buffered saline (PBS) pH 7.4 at 25° C, overnight while 
shaking. Excess PEG is removed using ion exchange chromatography followed by gel 
chromatography to separate uncoupled peptide from peptide-PEG. 
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Figure 4.2 Design of tumor-activated polymer gene delivery vectors using protease-
sensitive electrostatic coatings. Plasmid DNA is complexed with C32-117 to yield highly 
cationic gene delivery nanovectors with limited serum stability. Electrostatic adsorption 
of poly(glutamic acid) peptides terminated in protease-cleavable poly (ethylene glycol) 
(Pep-PEG) stabilizes the complex in serum and veils gene delivery function. Unveiling of 
the polymer coat by tumor associated proteases restores transfection and directs gene 
delivery to the surrounding cancer cells. 
 
The complexing of plasmid DNA with a cationic poly (β amino ester) C32-117 
into nanovectors followed by the electrostatic coating of protease responsive peptide-
PEGs is illustrated in Figure 4.2. C32-117 is a biodegradable poly β-amino esters that 
was identified from a library screen of structurally unique polymers and engineered to 
have terminal cationic domains to achieve superior transfection capacity[9-11]. This 
polymer belongs to a large group of cationic polymers that self-assemble with DNA into 
gene delivery nanovectors, as a result the coating technique described here could 
potentially be adapted to a variety of polymer systems such as polyethylenimine and 
PAMAM dendrimers. C32-117 is combined with plasmid DNA at a 40:1 w/w 
(weight/weight) ratio in 25mM sodium acetate buffer pH 5.0. The sample is vortexed and 
incubated for 10 min at 25° C. The resulting nanovectors have efficient, but non-specific 
transfection potential and limited stability in serum. Modification of C32-117 
nanovectors with a protease removable polymer coat is achieved by the electrostatic 
adsorption of peptide-PEG at a 25:1 peptide-PEG to DNA w/w ratio in 25mM sodium 
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acetate buffer pH 5.0 after vortexing and incubation for 10 min at 25° C. The resulting 
nanovectors are serum stable, but have significantly attenuated gene delivery function. 
Upon activation by tumor-associated MMPs, PEGs are removed to unveil the function of 
the resulting peptide coated nanovector, which effectively delivers genes to local cells. 
 
Figure 4.3 Incubation of uncoated C32-117 nanovectors in 10% serum leads to a loss in 
gene delivery function over time. 
 
While C32-117 has been reported to have good transfection capability after 
immediate mixing with serum over cells, its long-term stability and function in serum has 
not been tested. To analyze the effect of serum on the function of C32-117 nanovectors 
over time, we formulated uncoated vectors with GFP plasmid DNA and pre-incubated 
them for various times in serum or serum-free media before exposing to HT1080 cells. 
Nanovectors were incubated over cells for 3 hrs, after which cells were washed and the 
transfection efficiency was analyzed by flow cytometry after 24 hrs. Nanovectors 
incubated in media in the absence of serum retained transfection efficiency for several 
hours. In contrast, the transfection efficiency of nanovectors in media containing 10% 
serum was significantly reduced; after 2 hr the transfection dropped over four fold and 
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after 3 hrs the transfection efficiency had decreased to less than 5% relative to vectors 
placed over cells immediately (Figure 4.3). 
We hypothesized that the loss of function of C32 nanovectors in serum may be 
due to the interaction of anionic proteins with the cationic vector surface. We surmised 
that coating of the vector surface with electrostatically adsorbed peptide-PEG could 
reduce these adverse interactions, both veiling and preserving the function of gene 
delivery vectors over time. We electrostatically adsorbed non-cleavable (D-isomer) 
peptide-PEG coatings on nanovectors at varying densities and compared these to peptide 
coatings without PEG to mirror the gene delivery potential of vectors after the PEG is 
removed. Nanovectors were mixed with various weight ratios of peptide or peptide-PEG; 
0, 2.5, 5, 10, 15, 20, and 25 fold excess weight peptide over DNA. Vectors were 
incubated in 10% serum containing media for 3 hours, the time sufficient for uncoated 
vectors to degrade. Nanovectors were then incubated over cells for 3 hrs and the cells 
were subsequently washed and analyzed for GFP transfection by flow cytometry.  
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Figure 4.4 Increasing densities of electrostatic peptide coatings protect nanovector 
function from serum degradation after 3 hrs. Peptide-PEG coatings improve gene 
delivery function at low densities and effectively veil gene delivery at high densities. 
 
Figure 4.4 demonstrates the effect of varying densities of non-cleavable (D-
isomer) peptide-PEG and peptide coatings on nanovector function. Uncoated vectors (0 
w/w) had very low function as expected because of serum degradation. Peptide coatings 
at 2.5 w/w were able to preserve some transfection activity, and coatings of 5 w/w and 
above stabilized the GFP transfection, delivering GFP to 30-40% of the cell population. 
The stabilization of the nanovectors by higher densities of peptide coatings is likely due 
to the deterrence of serum protein interactions by the neutralizing coat. Peptide-PEG 
coated nanovectors stabilized nanovector function similarly to peptide-coated vectors at 
partial densities, but at higher densities the entropic penalty of PEG on the nanovector 
surface veils gene delivery. Compared to peptide only coatings, 25 w/w peptide-PEG 
coatings reduce gene transfection by more than 85%.  
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Figure 4.5 Serum protein interactions with uncoated nanovectors change their surface 
potential from positive to negative. Peptide-PEG coatings neutralize the nanovector 
surface potential and prevent adverse interactions with serum proteins. Peptide-PEG 
coated vectors also maintain a smaller size in serum (69nm) compared to uncoated 
vectors (182 nm) (error bars and +- are standard deviation of 3 separate measurements). 
 
 To investigate the mechanism of nanovector degradation in serum and the 
protective effects of peptide-PEG coatings, we observed the size and zeta potential of 
coated and uncoated vectors in 10% serum containing media. We found that interactions 
with serum proteins modify the surface potential of C32-DNA nanovectors from positive 
zeta potential to negative. The adsorption of anionic serum proteins, which give rise to 
this surface potential change may explain loss of activity from uncoated vectors over 
time. A 25 w/w ratio coating of peptide PEG reduces the positive zeta potential of 
nanovectors to near neutral levels. This surface potential is not significantly altered in 
serum containing media. Peptide-PEG coated nanovectors also maintain a reduced 
hydrodynamic diameter (69nm) over uncoated nanovectors  (182nm) when incubated in 
serum media (Figure 4.5). Both the neutralization of the surface potential and size 
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stabilization are indicators that Electra statically adsorbed peptide-PEG coatings do 
stabilize vectors in serum. 
 
Figure 4.6 Exogenous MMPs activate gene delivery by nanovectors with cleavable (L-
isomer) peptide-PEG coatings but not uncleavable (D-isomer) analogs. 
 
 Having demonstrated the role peptide-PEG coatings in stabilizing vectors and 
veiling function, we sought to test whether nanovectors would recover gene delivery 
function after their PEG coating is proteolytically removed. We coated vectors with 
cleavable (L-isomer) peptide-PEG and non-cleavable (D-isomer) control analogs at a 25x 
w/w ratio and activated these with MMPs (100 ug/ml) for 2 HR to pre-cleave PEG from 
the nanovector coatings. Vectors were then incubated in serum-containing media for 3 
hours before placing over HT-1080 cells. Nanovectors were washed after 3 hrs and GFP 
expression was measured 24 hrs later. Figure 4.6 shows that the removal of PEG by 
MMPs from the cleavable peptide-PEG coating indeed restores gene delivery. The level 
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of GFP transfection from cleavable peptide-PEGs not activated by MMPs and from non-
cleavable coatings both with and without MMP activation was indistinguishable from 
non-transfected control cells. The significant and specific induction of gene delivery by 
MMPs demonstrates the potential of this coating approach for spatially and temporally 
localizing the function of cationic polymer nanovectors to areas of local MMP 
expression.  
 
Figure 4.7 Endogenously produced MMPs from HT-1080 fibrosarcoma cells activate 
gene delivery from nanovectors with cleavable peptide-PEG coatings during a 48 hr 
incubation.  
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Figure 4.8 Representative phase and fluorescent micrographs of individual HT-1080 
cells demonstrate activated gene delivery by EGFP nanovectors from endogenously 
produced MMPs. 
 
Having demonstrated protease activation of the electrostatic coating with 
exogenous proteases, we sought to test whether MMPs endogenously produced over HT-
1080 cells could activate local gene delivery. To this end nanovectors with cleavable (L-
isomer) peptide-PEG and non-cleavable (D-isomer) control analogs at a 25x w/w ratio 
were incubated over HT1080 cells for 48 hr and the level of GFP expression was 
analyzed by flow cytometry. Indeed we found that cleavable peptide-PEG nanovectors 
had significantly improved transfection over non-cleavable controls (Figure 4.7). Phase 
and fluorescence micrographs of these cells demonstrate this enhanced GFP expression in 
Figure 4.8. 
 
 
4.3 Methods 
Unless otherwise stated all reagents were purchased from Sigma-Aldrich and all 
reactions were performed at room temperature. 
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Peptide-PEG Conjugation: The peptides used in this work were synthesized from 
the MIT Biopolymers core to contain an amino terminus for poly (ethylene glycol) 
succinimidyl valerate (PEG-SVA) coupling, a tetramethylrhodamine (TAMRA) labeled 
lysine, a matrix metalloproteinase-2 (MMP-2) cleavable domain, and a 16-mer poly 
(glutamic acid) (Poly-E) tail. The purity of the cleavable peptide, NH2-GK(TAMRA)-
GPLGVRG-GGGGGG-EEEEEEEEEEEEEEEE-CONH2, and the non-cleavable D-
isomer, NH2-GK(TAMRA)-GdPdLGdVdRG-GGGGGG-EEEEEEEEEEEEEEEE-
CONH2, were verified by HPLC and mass spectrometry. Amine reactive 10 kDa PEG-
SVA was purchased from Laysan Bio, Inc. Peptide at 160 µM was reacted with 10x 
excess molar PEG-SVA in phosphate buffered saline (PBS) pH 7.4, overnight while 
shaking. Free PEG was removed by ion exchange chromatography using DEAE 
Cellulose beads. Free peptide was removed by filtering on a G-50 Sephadex column. The 
purified peptide-PEG was transferred into sodium acetate using 3K Amicon centrifugal 
filters (Millipore) and its purity verified using MALDI (Supplementary Figure 1).  
 
C32-117 Synthesis: The synthesis of C32-117 was performed according to 
published protocols[11].  Briefly, 344 mg of 5-aminopentanol was weighed into a 1 mL 
sample vial with a Teflon-lined screw cap. Next, 793 mg of 1,4-butanediol diacrylate was 
added to the vial along with a small Teflon-coated stir bar. Monomers were polymerized 
on a magnetic stir-plate residing in an oven at 95°C for 1 day.  The acrylate-terminated 
polymer was then dissolved in DMSO at 31.13% wt/wt. An end chain capping reaction 
was performed by mixing 321 mg of polymer/DMSO solution with 800 µl of 1,3-
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diaminopentane dissolved in DMSO at 0.25 M. Reactions were performed in eppendorf 
tubes with constant agitation for 1 day. Upon completion, the vial was removed from the 
oven and stored at -20°C. C32 was analyzed by gel-permeation chromatography (GPC). 
 
Nanovector Formulation: C32-117 and DNA nanovectors are formed by the 
electrostatic complexation of the cationic C32-117 polymer with negatively charged 
pEGFP-N1 DNA (Elim Biopharmaceuticals) at a 40:1 polymer to DNA weight. DNA at 
0.12 mg/ml in NaAc buffer (25mM NaAc pH 5.0) is added to an equal volume of C32-
117 at 4.8 mg/ml in NaAc buffer, vortexed, and incubated for 10 minutes. Afterwards an 
equal volume of NaAc buffer containing 0, 0.3, 0.6, 1.2, 1.8, 2.4 or 3 mg/ml of free 
peptide or peptide-PEG was added to the nanovectors to form uncoated or varying weight 
ratios of coated particles.  
 
Cell culture and transfection: All experiments were performed with HT1080 
fibrosarcoma cancer cells (ATCC), which were maintained in DMEM medium (GIBCO) 
containing 10% fetal bovine serum (GIBCO) and 1% Pen Strep (GIBCO). Approximately 
1.2x106 per well HT-1080 cells were plated in 96 well plates and incubated for 24 hrs 
before transfection. Coated and uncoated nanovector formulations were diluted in serum 
containing media at 1 part nanovector formulation and 5 parts media. This solution was 
incubated from 0 to 3 hrs to account for serum-particle interactions. To each well was 
added 150 µl of nanovector-media solutions and 2.68 µl of a pH balancing solution (1M 
HEPES 1.5M NaCl 82mN NaOH) for a total of 750 ng DNA per well. Nanovectors were 
incubated over cells for 3 hrs. Afterwards the medium was replaced by DMEM 
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containing serum, and GFP expression in transfected cultures was measured by flow 
cytometry 24 hrs later.  
 
Flow Cytometry and Microscopy: Attached cells were cleaved by 5 min 
incubation with 0.25% trypsin with EDTA (GIBCO) and trypsin was quenched by 
diluting the cell suspension in 1% BSA in phosphate buffered saline. Detached cells were 
analyzed on a BD LSR II flow cytometer with a 488nm excitation source and a 530/30 
bandpass filter for GFP expression and 570/36 bandpass filter for autofluorescence (PE) 
detection. The percentage of GFP positive cells was determined by gating non-
fluorescing control cells on a 2-D scatter plot with axes of autofluorescence (PE) and 
GFP. The mean GFP signal was determined by a gating of all cells. Analysis and gating 
was performed using FlowJo software. Microscopy was conducted on attached cells prior 
immediately before flow cytometry using a 20x objective and a FITC filter cube 
(Chroma). 
 
Dynamic Light Scattering (DLS) and Zeta Potential: For sizing measurements 1 
volume of coated or uncoated nanovectors was added to 5 volumes of DMEM media 
containing 10% FBS. Dynamic light scattering was used to determine the hydrodynamic 
diameter of vectors for 3 separately formulated solutions using a Niño – ZS90 (Malvern). 
For zeta measurements 1 volume of coated or uncoated nanovectors was added to 5 
volumes of DMEM media either with or without 12% FBS. Zeta measurements were 
taken for 3 separately formulated solutions using a Nano – ZS90 (Malvern). 
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Exogenous MMP activation: Cleavable and non-cleavable Peptide-PEG coated 
nanovector formulations were diluted in DMEM media at 1 part nanovectors, 4.5 parts 
media, and 0.11 parts of pH balancing solution. Collagenase (SIGMA) at 100ug/ml was 
added to the nanovector media solution and incubated for 2 hrs to pre-cleave the MMP 
sensitive peptide-PEG. FBS (0.5 parts) was added to the nanovector-media solution and 
incubated for 3 hrs to account for the effect of serum on these vectors. To each well on a 
96-well plate was added 150 µl of the nanovector-media (750 ng DNA). After 3 hrs the 
cells were washed and replaced with serum media. After 24 hrs the cells were analyzed 
by flow cytometry. 
 
Endogenous MMP activation: Cleavable and non-cleavable peptide-PEG coated 
nanovector formulations were diluted in serum containing media at 1 part nanovector 
formulation and 5 parts serum containing media. This solution was incubated for 3 hrs to 
account for the effect of serum on these vectors. To each well was added 150 µl of 
nanovector-media solutions and 2.68 µl of a pH balancing solution (1M HEPES 1.5M 
NaCl 82mN NaOH) for a total of 750 ng DNA per well. Nanovectors were incubated 
over cells for 48 hrs. Afterwards the medium was replaced by DMEM containing serum, 
and GFP expression in transfected cultures was measured by microscopy and flow 
cytometry 24 hrs later. 
 
4.4 Conclusion 
In this work we have developed a simple coating strategy for stabilizing and 
transiently veiling the activity of cationic polymer gene delivery nanovectors. Using 
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functional and biophysical measurements we show that electrostatically adsorbed 
protease-sensitive PEG coatings effectively shield nanovectors from adverse serum 
interactions. We verify that proteolytic cleavage of the removable polymer restores 
nanovector function localizing gene delivery in time and space. Recent work by us and 
others have demonstrated the potential for protease removable coatings to enhance the 
overall accumulation of nanoparticles modified with cationic domains in tumors, while 
allowing the function of these vectors to be unveiled by tumor-associated proteases in 
vivo[3, 12].  This simple and easily applied coating system not only enables this strategy to 
be applied to C32-117 nanovectors, but could be adapted to a variety of other cationic 
nanovectors carrying a multiplicity of other payloads for tumor therapy. 
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Chapter 5: Organ Specific Polymer Gene Delivery via 
Simple Tuning of Electrostatic Coatings 
5.1 Introduction 
Viruses have evolved incredible efficiency and control over gene delivery through 
selective alterations to exterior and interior proteins that mediate serum stability, target 
cell specificity, endosomal escape and nuclear transport. With synthetic gene delivery 
vectors, the interior and exterior composition of polyplexes are often coupled, with a 
single polymer backbone governing all functions from DNA condensation to nuclear 
delivery and release[1, 2]. As a result the parameter space for improving gene delivery is 
not easily expanded, with each selective alteration requiring a re-synthesis of the core 
polymer. Furthermore, efforts to covalently modify core polymers with poly(ethylene-
glycol) (PEG)[3, 4] and or targeting ligands[5-9] have produced mixed results with some 
groups reporting significant gains in transfection efficiency and others reporting none[7-
10].  
In this work we demonstrate a simple method for applying electrostatically 
adsorbed peptide coatings to alter the exterior composition of a core gene delivery vector 
and tune these for efficient and selective gene delivery function in vivo. Surprisingly, we 
find that variations in coating density and peptide domains can guide gene delivery 
vectors to different organs and significantly reduce the morbidity associated with cationic 
gene delivery polyplexes. Using one of these formulations we successfully deliver a 
Factor IX plasmid to the liver and achieve sustained protein expression in the blood. 
Using another formulation we demonstrate gene delivery to monocyte and T-cells in the 
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bone marrow. This simple coating strategy provides a highly tunable method for 
achieving spatial control of polymer gene delivery vectors in vivo. 
 
5.2 Results and Discussion 
 
Figure 5.1 Electrostatic coatings applied to cationic nanovectors target gene delivery to 
specific organs. Cationic nanovectors, formed by complexing the poly (β amino ester) 
C32-117 with plasmid DNA at a 30x polymer:DNA weight/weight ratio (w/w), are 
coated with (glutamic acid) peptides (poly-Es) at varying surface densities. Poly-Es 
adsorbed at a lower surface density, 2.5x Poly-E:DNA w/w, increase the size and lower 
the surface potential of polyplexes to enable highly specific and efficient gene delivery to 
the liver. Poly-Es adsorbed at a higher surface density, 20x Poly-E:DNA w/w, reduce the 
size of nanovectors and eliminate liver delivery, but the addition of a terminal cationic 
sequence that increases the surface potential of the polyplex activates gene delivery to the 
marrow and spleen. 
 
Figure 1 schematically depicts a strategy for organ specific gene delivery through the 
simple tuning of electrostatic peptide coatings on intravenously injected cationic 
nanovectors. The poly (β amino ester) C32-117 is complexed with plasmid DNA at a 30x 
polymer to DNA weight/weight ratio (w/w) to form a cationic nanovector. Poly (glutamic 
acid) (poly-E) peptides are applied to coat these vectors in a simple mixing procedure. 
Peptides added at varying weight ratios modulate both the size and surface potential of 
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nanovectors. Two coating formulations are found to efficiently target intravenously 
injected nanovectors to specific organs in vivo. Low-density poly-E peptide coatings give 
rise to large particles with a negative zeta potential that target genes to the liver. High-
density poly-E peptide coatings form small nanoparticles that target the marrow and 
spleen when modified with a terminal cationic sequence insert. 
 
Figure 5.2 Near infrared fluorophore labeled DNA accumulates in the lungs of animals 
injected with a lethal dose (50 ug DNA) of non-coated vectors. Animals injected with the 
same dose of 2.5x w/w poly-E coated vectors tolerate the injection well and show no lung 
accumulation when sacrificed at 24 hr post injection. 
 
 Intravenously administered cationic polymer gene vectors have demonstrated the 
capacity to deliver genes with high efficiency to the lung, however this effective delivery 
is correlated with toxic side-effects[11]. When injected intravenously, cationic vectors 
aggregate with serum proteins and erythrocytes to form complexes that embolize to 
vascular beds in the lung[12-14]. We observed similar behavior from C32-117 nanovectors. 
A 50ug dose of complexed DNA was lethal in 50% of injected mice. Accumulation of 
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fluorescently labeled DNA can be seen in the lungs of animals injected with this lethal 
dose Figure 5.2. In an effort to reduce the toxic effects of intravenously administered 
cationic nanovectors, we sought to develop and characterize a series of electrostatic 
peptide coatings that could neutralize vector surface potential and alter their function in 
vivo. We coated C32-117 nanovectors with varying w/w ratios of a 16mer poly (glutamic 
acid) peptide terminated in a short glycine sequence. Animals were dosed with 50ug of 
complexed pCMV-LUC plasmid DNA and gene delivery was measured by luciferase 
expression from ROIs around organs in whole body luminescence imaging. 
 
Figure 5.3 Whole mouse bioluminescence imaging of mice injected with 50ug of 
pCMV-LUC plasmid DNA complexed with C32-117 and coated with varying densities 
of Poly-E peptides. [*] A maximum non-lethal dose of 25ug was used for non-coated 
controls. 
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Figure 5.4 ROI analysis of lungs liver, spleen, and femur bone marrow demonstrates 
specific and dose responsive liver delivery by poly-E peptide coated vectors. Vectors 
with poly-E coatings at 2.5x w/w are well tolerated and target high levels of luciferase 
expression to the liver. Gene delivery is reduced with higher coating densities. Graph 
shows mean and S.D. of n=3 animals. 
 
 We found that coating density has a substantial effect on the function of cationic 
nanovectors. Nanovectors coated with a 2.5x w/w ratio of Poly-E peptides are well 
tolerated in mice and show significantly enhanced gene expression in the liver compared 
to uncoated vectors administered at a non-lethal dose of 25ug DNA (Figure 5.3 and 5.4). 
This liver transfection decreases with increasing poly-E coating density. At a 20x coating 
density nanovectors have nearly undetectable gene expression.  
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Figure 5.5 Non-coated vectors have a positive zeta potential that becomes negative when 
incubated in serum. The adsorption of poly-E coatings shifts the nanovector surface 
potential to negative in serum and serum free buffer. Data is n=3 separately formulated 
solutions. 
 
Figure 5.6 C32-117 nanovectors aggregate freshly isolated erythrocytes when mixed in 
vitro, while poly-E coated nanovectors have no effect. 
 
To understand the mechanism of efficiency and toxicity improvements seen with 
poly-E coatings, we characterized the biophysical properties of coated and uncoated 
vectors. We found that the adsorption of poly-E coatings had a substantial effect on 
nanovector surface potential and size. In pH 7.4 buffer poly-E coatings shifted the zeta 
potential of C32 nanovectors from positive to negative. (Figure 5.5). We surmised that 
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this surface potential could play a role in reducing erythrocyte aggregation and lung 
embolization. Indeed, when incubated with freshly isolated erythrocytes, uncoated 
vectors visibly aggregate red blood cells, while vectors coated with poly-E peptides have 
no effect (Figure 5.6). 
 
Figure 5.7 Dynamic light scattering shows coating dependent changes in nanoparticle 
size that coincide with liver delivery function. Lower coating densities, which have high 
transfection efficiency, form micron sized particles, while the highest density coating, 
which shows low transfection efficiency, form ~200nm vectors. Data is n=3 separately 
formulated solutions. 
 
While reductions in toxicity from surface potential neutralization could be 
anticipated, the improvements in liver directed delivery by partially coated vectors was 
unexpected. An investigation into the size of complexes formed by various coating 
densities provides some insight into the mechanism of how this improved liver delivery 
may be achieved. We found that the adsorption of 2.5x w/w poly-E coatings leads to a 
significant increase in vector diameter from ~400nm to ~2500nm (Figure 5.7). When 
higher coating densities were applied, the size of nanovectors decreased, with the highest 
density (20x) condensing nanovector size from ~400nm to ~200nm. Previous reports 
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have demonstrated that micron size polyplexes injected in the portal vein transfect liver 
cells more efficiently than smaller counterparts[15]. The particle sizes we observed support 
this observation, while enabling liver directed polymer gene delivery through a simple 
intravenous route. 
 
Figure 5.8 Histological analysis of mouse livers 6 hrs post injection of 2.5x poly-E 
coated pEGFP-N1 gene delivery vectors show gene expression in both CD31 positive and 
negative vessels. GFP expression also colocalizes in Kupffer cells (F4-80) near vessel 
borders. 
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Figure 5.9 Flow cytometry of freshly isolated hepatocytes 6hrs post injection of 2.5x 
poly-E coated vectors shows no transfection of hepatocytes. 
 
Given the improvements in liver transfection by partially coated vectors observed 
in whole body luminescence, we sought to determine the specific cell types being 
targeted by these vectors in the liver. To do so, we analyzed histological sections of livers 
from mice 6 hrs after injection with 50 ug of complexed pEGFP-N1 plasmid DNA GFP 
staining was present throughout the liver and localized to the lining and periphery of both 
CD31 positive and CD31 negative vessels. GFP signal also co-localized with F4-80 
positive kupffer cells near the vessel linings (Figure 5.8). To determine if GFP was 
targeted to the hepatocytes, we isolated these cells from livers at 6 hrs after injection of 
2.5x poly-E coated vectors and analyzed GFP expression by flow cytometry. We did not 
find GFP expression in hepatocytes from livers transfected with the coated vector 
(Figure 5.9). 
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Figure 5.10 Systemically administered partially coated human Factor IX (hFIX) gene 
delivery vectors establish prolonged expression of hFIX in the blood. 
 
Given the efficient and specific liver transfection achieved with partially coated 
nanovectors, we attempted to use these materials to deliver a therapeutically relevant 
gene to the liver. Hemophilia, a genetic disorder wherein there is a gene deletion or 
mutation of one of the factors involved in the coagulation cascade, is one disease among 
a class of disorders that could be cured by safe, effective, and stable gene delivery to the 
liver[16]. Using a human Factor IX mini-circle plasmid[17, 18], we injected 50ug of 
complexed DNA and measured the presence of Factor IX in the blood at 2 days and 2 
weeks post injection. We found that partially coated vectors effectively delivered the 
human Factor IX gene to mice, achieving concentrations of 3 ng/ml with 2.5x w/w poly-
E coatings and 2 ng/ml by 5x w/w poly-E coatings (Figure 5.10). While these protein 
levels are approximately an order of magnitude lower than what is necessary for 
therapy[19], it may be possible to achieve therapeutic level by modulating the dosing 
regimen to inject more DNA or perform multiple injections over several days.  
 121 
 
Figure 5.11 Whole mouse bioluminescence imaging of mice injected with 50ug of 
pCMV-LUC plasmid DNA complexed with C32-117 and coated with 20x w/w poly-E-
cat peptides shows gene expression localized in the spleen and marrow rich bone 
structures. 
 
Figure 5.12 Fold enhancement in luciferase expression in ROIs of lungs liver, spleen, 
and marrow by nanovectors coated with poly-E-cat peptides relative to vectors coated 
with poly-Es. 
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Figure 5.13 Dynamic light scattering shows that 20x poly-E and poly-E-cat coatings 
condense cationic nanovectors to ~200nm in serum media. 
 
Figure 5.14 Zeta potential analysis of nanovectors in serum and serum-free media shows 
that 20x poly-E-cat coatings shift the nanovector surface potential towards positive. 
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Figure 5.15 C32-117 nanovectors coated with 20x w/w poly-E and poly-E-cat peptides 
do not aggregate freshly isolated erythrocytes when mixed in vitro. 
 
At a 20x density poly-E coatings form condensed, negatively charged nanovectors 
that are not effective in transfecting genes in mice. We hypothesized that alterations in 
the terminal sequence of poly-E peptides at these higher densities could modulate and 
improve gene delivery function. We tested peptides with other terminal sequence inserts 
and found one that provided a unique gene delivery profile to the marrow and spleen. 
Nanovectors coated with this peptide, which we call poly-E-cat because it contains the 
cationic amino acid sequence G-dP-dL-G-dV-dR-G between the K(TAMRA), delivered 
GFP to the spine, skull, sternum, and femur of mice (Figure 5.11). These regions had 
substantially higher gene expression when vectors were coated by 20x w/w poly-E-cat 
peptides compared to vectors coated by poly-Es. ROIs selected around the femur bones 
showed nearly 40-fold enhancement by poly-E-cat coated vectors over poly-E coated 
ones and regions around the spleen showed nearly 30-fold enhancement (Figure 5.12). 
Vectors coated with these peptides had similar sizes, both condensing to less than 200nm 
over the course of 15 min (Figure 5.13). However, the zeta potential of vectors coated 
with poly-E-cat peptides are neutral, which is shifted positive from poly-E coated vectors, 
which are negative (Figure 5.14). This neutralizing of the surface potential may play a 
role in the functional differences of these two vectors. Vectors coated by 20x w/w poly-
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E-cat peptides were tolerated well in mice and did not aggregate freshly isolated 
erythrocytes (Figure 5.15). 
 
Figure 5.16 Flow cytometry analysis of marrow cells from a mouse injected with GFP 
transfecting nanovectors coated with 20x poly-E-cat peptides shows that certain cell 
types including monocyte and T-cell lineage cells have enriched GFP expression relative 
to the whole bone marrow cell population. 
 
To examine which cells are transfected in the bone marrow, we isolated marrow 
cells from the femur of a mouse 6 hrs after injecting vectors coated with poly-E-cat 
peptides and performed flow cytometry. Cells were labeled with various markers to 
identify specific cell subtypes and the percentage of cells expressing GFP in each cell 
type was compared to the whole bone marrow cell population. Cells positive for the 
monocyte marker GR1 had nearly 40-fold enrichment of GFP expression over the whole 
cell population and T-cells, in particular CD8 T-cells, were enriched nearly 25-fold 
(Figure 5.16). This enrichment corresponds to gene transfection of 1 in 204 GR-1 
positive monocytes and 1 in 313 CD8 positive T-cells. While these levels of transfection 
may not be sufficient for gene delivery strategies that require transfection of the entire 
monocyte or T-cell population, this technique could be used to delivery genes to a portion 
of cells, which would subsequently migrate to peripheral tissues and express protein. 
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Furthermore strategies to improve the number of transfected cells including increased 
dose of DNA, multiple injections, or modifications to the amino acid sequence in the 
terminal insert could significantly improve these levels. 
 
5.3 Methods 
Unless otherwise stated all reagents were purchased from Sigma-Aldrich and all 
reactions were performed at room temperature. 
 
Electrostatic Peptide synthesis: The peptides used in this work were synthesized 
by the MIT Biopolymers core and their purity was verified by HPLC and mass 
spectrometry. The poly-E peptide sequence is NH2-GK(TAMRA)-GGGGGG-
EEEEEEEEEEEEEEEE-CONH2. The poly-E-cat peptide sequence is NH2-
GK(TAMRA)-GdPdLGdVdRG-GGGGGG-EEEEEEEEEEEEEEEE-CONH2.  
 
C32-117 Synthesis: The synthesis of C32-117 was performed according to 
published protocols[20].  Briefly, 344 mg of 5-aminopentanol was weighed into a 1 mL 
sample vial with a Teflon-lined screw cap. Next, 793 mg of 1,4-butanediol diacrylate was 
added to the vial along with a small Teflon-coated stir bar. Monomers were polymerized 
on a magnetic stir-plate residing in an oven at 95°C for 1 day.  The acrylate-terminated 
polymer was then dissolved in DMSO at 31.13% wt/wt. An end chain capping reaction 
was performed by mixing 321 mg of polymer/DMSO solution with 800 µl of 1,3-
diaminopentane dissolved in DMSO at 0.25 M. Reactions were performed in eppendorf 
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tubes with constant agitation for 1 day. Upon completion, the vial was removed from the 
oven and stored at -20°C. C32 was analyzed by gel-permeation chromatography (GPC).  
 
C32-117 and DNA nanovector formulation: C32-117 and DNA nanovectors were 
formed by complexing positively charged C32-117 with negatively charged plasmid 
DNA at a 30:1 polymer to DNA wt/wt ratio. One volume of DNA at 1mg/ml in NaAc 
buffer (25mM NaAc pH 5.0) was mixed with one volume of C32-117 at 30 mg/ml in 
NaAc buffer and incubated for 5 min. To this formulation was added one volume of poly-
E peptide at 0, 2.5, 5, 10 or 20 mg/ml followed by mixing and incubation for 5 min. 
Finally, one volume of 20% glucose in phosphate buffered saline (PBS) was added 
immediately before intravenous injections or biophysical characterization. In some of the 
injected formulations Alexa-680 labeled DNA was spiked in at a 1 to 10 w/w dilution for 
tracking accumulation.  
 
DNA labeling: Free thrills were coupled on the backbone using the FastTag 
reagent kit (Vector) according to the manufacturer’s protocol. Alexa-680 maleimide 
(Invitrogen) was attached to the free thiols and the labeled DNA was purified on a G50 
gel filtration column. 
 
Bioluminescence imaging: Swiss Webster mice were intravenously injected with 
50 µg of complexed and coated pCMV-LUC plasmid DNA in 200 µl intravenously. After 
6 hrs, animals were injected i.p. with 4.5 mg of luciferin (Promega) in 300 µl and the 
level of luciferase gene expression was quantified using an IVIS whole mouse 
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bioluminescence imaging system (Xenogen). Animals were imaged on their abdomen 
and back and ROIs were drawn around the spleen from a posterior view and the liver, 
femurs, and lungs from an anterior view. 
 
Sizing and zeta potential: For sizing measurements 1 volume of coated or 
uncoated nanovectors was added to 7 volumes of PBS containing 12% fetal bovine serum 
(FBS). Dynamic light scattering was used to determine the hydrodynamic diameter of 
vectors at various time points for 3 separately formulated solutions using a Nano – ZS90 
(Malvern). For zeta measurements 1 volume of coated or uncoated nanovectors was 
added to 7 volumes of PBS with or without 12% FBS. Zeta measurements were taken for 
3 separately formulated solutions using a Nano – ZS90 (Malvern). 
 
Erythrocyte aggregation assay: Fresh mouse blood was isolated and added to an 
equal volume of buffer containing PBS and 10mM EDTA. Erythrocytes were pelleted by 
centrifugation, washed multiple times in PBS, and diluted 4-fold. To one volume of fresh 
erythrocytes was added one volume of coated or uncoated C32-117 nanovectors. 
Solutions were incubated for 1 hr at 37 °C and diluted 40-fold into a 96-well plate for 
phase contrast imaging.  
 
Histology: Mouse livers isolated 6 hrs post injection of 2.5x w/w poly-E coated 
nanovectors were frozen in OCT compound for sectioning. Liver sections were fixed 
with cold acetone, washed in PBS and incubated in blocking buffer (PBS + 12% FBS) for 
20 minutes. Sections were then washed and incubated with rat anti-F480 IGG () or rat 
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anti-CD31 IGG (BD Pharmingen) and rabbit anti-GFP IGG (ABD Serotec) for 24 hrs. 
Sections were washed and a secondary stain of alexa 546-labeled goat anti-rat IGG 
(Invitrogen) and alexa 647-labeled goat anti-rabbit IGG (Invitrogen) was applied for 1 
hour. The antibodies were washed and the sections were stained with 0.0001% Hoechst 
for 20 min prior to mounting with Fluor mount-G (Southern Biotech). Liver sections 
were imaged on an inverted fluorescence microscope mounted with a CCD camera 
(Nikon Ellipse TE200 and CoolSnap-HQ). UV, Texas red, and Cy5 filter cubes (Chroma) 
were used to image nuclear, antigen, and GFP stains respectively. 
 
Hepatocyte isolation: Hepatocytes were isolated from mice 6 hrs after injection 
with 2.5x w/w poly-E coated vectors using a modified procedure developed in rats[21]. 
Hepatocytes were purified from the rest of the cell population with multiple centrifugal 
spins at 500 rpm in KRB buffer. Cells were resuspended in FACs buffer (PBS with 1% 
FBS) and analyzed by flow cytometry.  
 
Bone marrow isolation and labeling: Bone marrow cells were isolated from mice 
6 hrs after injection with 20x w/w poly-E-cat coated vectors. The bone marrow was 
triturated from the femur and tibia bones with RPMI media (GIBCO) containing 5% FBS 
using a 28 gauge syringe and passed through a 70 µm cell strainer. Cells were centrifuged 
at 1000 rpm and resuspended in 1 ml of RBC lysis buffer. After a 5 min incubation cells 
were diluted in RPMI media with 10% serum and centrifuged at 1260 RPMs for 5 min at 
4 °C.   Cells were washed 1x with FACs buffer and resuspended in 1ml of blocking 
solution made up of FACs buffer containing a 1:200 dilution of anti-mouse FcγIII/II 
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(Pharminogen). Cells were incubated for 5 minutes and 100 µl aliquots were removed 
and added to 100 µl of biotin-labeled primary Gigs diluted 1:100 in FACs buffer (anti-
mouse IGG control, TER-119, CD5, CD4, CD8, CD3, CD45R, GR1, and CdllB – 
Pharminogen). After a 20 min incubation, each aliquot was washed and incubated with a 
1:400 dilution of streptavidin-PE-Cy5 (Pharminogen) in FACs buffer. Cells were washed 
and resuspended in FACs buffer for flow cytometry. 
 
Flow cytometry: Isolated hepatocytes and bone marrow cells were analyzed on a 
BD LSR II flow cytometer with a 488nm excitation source and a 530/30 bandpass filter 
for GFP expression and 570/36 bandpass filter for autofluorescence (PE) detection, as 
well as a 405nm excitation source and a 670/14 bandpass filter for PE-Cy5 detection. The 
percentage of GFP positive cells was determined by gating non-fluorescent cells isolated 
from an untreated animal on a 2-D scatter plot with axes of autofluorescence (PE) and 
GFP. Fold enhancement of GFP expression for bone marrow cells was determined by 
dividing the percentage of GFP positive cells for a maker-positive subset over the 
percentage of GFP positive cells in the whole blood marrow population. Analysis and 
gating was performed using FlowJo software. 
 
Human factor IX injections: Experimental animals (n=3) were injected with 50ug 
of mini circle human Factor IX plasmid complexed in 2.5x or 5x poly-E coated vectors. 
At 2 days and 2 weeks post injection blood was drawn suborbitally and anticoagulated 
with citrate. Human Factor IX levels in the blood were determined using a competitive 
ELIZA assay. Experimental samples were compared to controls injected with buffer only. 
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5.4 Conclusion 
In this work we have demonstrated a simple and highly effective coating method to 
modify the function and toxicity of cationic gene delivery nanovectors. These coatings 
expand the available parameter space for modifying cationic gene delivery vectors by de-
coupling their biophysical properties from the condensing polymer backbone. We show 
that these simply tuned electrostatic coatings have the potential to transfect liver cells to 
achieve near therapeutic levels of FIX expression in the blood and to achieve specific 
gene delivery to the spleen and marrow. Given their profound effect on the functional and 
biophysical characteristics of cationic polyplexes, we anticipate that these electrostatic 
coatings could be used to target genes to a variety of organs, tissues and cells offering 
promising therapies for a host of diseases in which genetic manipulation could be 
curative. 
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Chapter 6: Future Directions for siRNA Delivery with 
Electrostatic Coatings2 
6.1 Introduction 
siRNA therapeutics hold great promise for the treatment of cancer, but effective 
delivery to tumors still limits this approach[1, 2]. While inherent in the design of siRNAs is 
high specificity for target gene knockdown, off target effects including the elicitation of 
cytokines or the repression of protein levels in non-target cells makes spatially and 
temporally controlled siRNA delivery important for clinical applications[3-6]. We 
previously demonstrated a protease-responsive electrostatic coating strategy that 
temporally controls the veiling and unveiling of gene delivery nanovectors in response to 
tumor proteases. We further demonstrated that simple tuning of electrostatic coatings 
could be used to spatially control the delivery of genes to tissues in vivo. Here we 
demonstrate that these same polymers and coatings may be used for effective siRNA 
delivery. Using the cationic poly (β amino ester) C32-117 and poly(glutamic acid) (poly-
E) coatings, we form siRNA polyplexes that knockdown gene expression in HeLa cells. 
Given the effect of electrostatic coatings on C32-DNA vectors, these C32-siRNA 
complexes could enable specific, effective, and controlled delivery of nucleic acids in 
vivo. 
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6.2 Results and Discussion 
 
Figure 6.1 Design of electrostatic coatings for polymer siRNA delivery. siRNAs are 
complexed with C32-117 to yield highly cationic delivery vectors. Electrostatic 
adsorption of poly-E peptide and peptide-PEG coatings provide tunable and responsive 
properties that can improve the delivery of siRNAs to cancer cells and direct these 
vectors to specific sites in vivo. 
 
The formation of nanovectors by complexation of siRNAs with C32-117 followed 
by the adsorption of poly-E peptide or peptide-PEG coatings is illustrated in Figure 6.1. 
C32 is mixed with siRNAs at a 40:1 w/w (weight/weight) ratio in 25mM sodium acetate 
buffer pH 5.0 and incubated for 10 min at 25° C. The resulting cationic nanovectors 
deliver siRNAs to cells, albeit non-specifically. Modification of C32-117 nanovectors 
with poly-E peptide and protease removable polymer coatings is achieved by mixing 
peptides and peptide-PEGs at varying w/w ratios with siRNA vectors in 25mM sodium 
acetate buffer pH 5.0 and incubating for 10 min at 25° C. In the case of peptide-PEG 
coatings, the resulting nanovectors are veiled in their initial state, but removal of PEGs by 
tumor associated MMPs reveal the underlying peptide-coated nanovector, which 
effectively delivers siRNAs to local cells. In the case of peptide coatings, properly tuned 
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adsorption of poly-E peptides alter the biophysical properties of siRNA nanovectors 
directing delivery to specific organs in vivo. 
 
 
Figure 6.2 C32-117 polymers effectively complex and deliver GFP siRNA to HeLa cells. 
  
 To investigate the capacity for C32-117 to deliver siRNA into cells and 
knockdown gene expression, we complexed GFP siRNAs with various w/w ratios of 
polymer and investigated the dose dependent knockdown of GFP expression after 
incubating these complexes for 4 hrs in serum free media over HeLa cells stably 
expressing GFP (Figure 6.2). C32-117 complexed with siRNA at a 40 w/w ratio was 
effective in knocking down GFP expression by 65% when incubated over cells at a 
concentration of 50 nM. This formulation proved to be slightly better than lipofectamine 
under these conditions. Lamin controls formulated at the same w/w ratios and 
concentrations have no effect on GFP expression. 
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Figure 6.3 Electrostatic peptide coatings effectively deliver and veil gene knockdown of 
siRNA polyplexes. A) All densities of poly-E peptide coatings preserve knockdown 
efficiency of C32-siRNA vectors, while Pep-PEG coatings reduce gene knockdown in a 
dose-dependent fashion. Lamin controls have no effect on gene expression. B) GFP 
knockdown by lipofectamine serves as a positive control. 
 
We next investigated whether poly-E peptide and peptide-PEG coatings can 
modulate the functional properties of siRNA-C32 complexes. We formulated C32-siRNA 
nanovectors with varying w/w ratios of poly-E and peptide-PEG coatings and 
investigated the knockdown of GFP expression by 100 nM siRNA complexes when 
incubated for 4 hrs in serum free media over HeLa GFP cells (Figure 6.3). Peptide-PEG 
coatings on siRNA vectors mimic the dose-dependent veiling of gene delivery by DNA 
vectors. Peptide-PEG coatings at a 20x w/w ratio veil nanovector function and minimize 
gene knockdown. When PEG is unattached, knockdown increases form 12% to 70%. 
Additionally, substantial gene knockdown is seen by nanovectors coated with all w/w 
ratios of poly-E peptide coatings. This preserved function across coating densities mimics 
the effect of poly-E coatings on DNA delivery vectors. Given the efficient and specific 
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organ delivery achieved by poly-E coated DNA nanovectors in vivo, it is anticipated that 
these coated siRNA vectors could achieve gene knockdown with similar efficiency and 
organ specificity. 
 
6.3 Methods 
Unless otherwise stated all reagents were purchased from Sigma-Aldrich and all 
reactions were performed at room temperature. 
 
Peptide-PEG Conjugation: The peptides used in this work were synthesized from 
the MIT Biopolymers core to contain an amino terminus for poly (ethylene glycol) 
succinimidyl valerate (PEG-SVA) coupling, a tetramethylrhodamine (TAMRA) labeled 
lysine, a matrix metalloproteinase-2 (MMP-2) cleavable domain, and a 16-mer Poly-E 
tail. A non-cleavable D-isomer, NH2-GK(TAMRA)-GdPdLGdVdRG-GGGGGG-
EEEEEEEEEEEEEEEE-CONH2, was used for both Poly-E peptide and peptide-PEG 
coatings. The purity of this peptide was verified by HPLC and mass spectrometry. 
Peptide at 160 µM was reacted with 10x excess molar 10 kDa PEG-SVA (Laysan Bio, 
Inc) in phosphate buffered saline (PBS) pH 7.4, overnight while shaking. Free PEG was 
removed by ion exchange chromatography using DEAE Cellulose beads. Free peptide 
was removed by filtering on a G-50 Sephadex column. The purified peptide-PEG was 
transferred into sodium acetate using 3K Amicon centrifugal filters (Millipore) and its 
purity verified using MALDI. 
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C32-117 Synthesis: The synthesis of C32-117 was performed according to 
published protocols[7].  Briefly, 344 mg of 5-aminopentanol was weighed into a 1 mL 
sample vial with a Teflon-lined screw cap. Next, 793 mg of 1,4-butanediol diacrylate was 
added to the vial along with a small Teflon-coated stir bar. Monomers were polymerized 
on a magnetic stir-plate residing in an oven at 95°C for 1 day.  The acrylate-terminated 
polymer was then dissolved in DMSO at 31.13% wt/wt. An end chain capping reaction 
was performed by mixing 321 mg of polymer/DMSO solution with 800 µl of 1,3-
diaminopentane dissolved in DMSO at 0.25 M. Reactions were performed in eppendorf 
tubes with constant agitation for 1 day. Upon completion, the vial was removed from the 
oven and stored at -20°C. C32 was analyzed by gel-permeation chromatography (GPC).  
 
Nanovector Formulation: C32-117 and siRNA nanovectors were formed by the 
electrostatic complexation of C32-117 with negatively charged GFP siRNA, sense strand: 
5′-GG CUA CGU CCA GGA GCG CAC C-3′ (Dharmacon), at a 40:1 polymer to siRNA 
wt/wt ratio. One part siRNA at 100nM in NaAc buffer (25mM NaAc pH 5.0) was mixed 
with one part C32-117 at 0.83 mg/ml in NaAc buffer and incubated for 10 min. 
Afterwards, one part of NaAc buffer containing 0, 0.05, 0.1, 0.2 or 0.4 mg/ml of free 
peptide or peptide-PEG was mixed with C32-siRNA and incubated for 10 min. 
Nanovectors were subsequently diluted, combined with media, and added over cells. 
 
Cell culture and transfection: All experiments were performed with HeLa cells 
stably expressing GFP (courtesy of Prof. Phillip Sharp) which were maintained in 
DMEM medium (GIBCO) containing 10% bovine serum (GIBCO) and 1% Pen Strep 
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(GIBCO). Approximately 17,000 HeLa cells per well were plated in 96 well plates and 
incubated for 24 hrs before transfection. To each well was added 30 µl of nanovector 
solution, 120 µl of serum free DMEM media, and 2.68 µl of a pH balancing solution (1M 
HEPES 1.5M NaCl 82mN NaOH). Nanovectors were incubated over cells for 4 hrs. 
Afterwards the medium was replaced by DMEM containing serum, and GFP knockdown 
was measured by flow cytometry 48 hrs later.  
 
Flow Cytometry: Attached cells were cleaved by 5 min incubation with 0.25% 
trypsin with EDTA (GIBCO) and trypsin was quenched by diluting the cell suspension in 
1% BSA in PBS. Detached cells were analyzed on a BD LSR II flow cytometer with a 
488nm excitation source and a 530/30 bandpass filter for GFP expression and 570/36 
bandpass filter for autofluorescence (PE) detection. The percentage of GFP positive cells 
was determined by gating non-fluorescing control cells on a 2-D scatter plot with axes of 
autofluorescence (PE) and GFP. Analysis and gating was performed using FlowJo 
software.  
 
6.4 Conclusion 
While the superior DNA transfection properties of C32-117 are well known, the 
ability of these polymers to knockdown siRNA has not been shown[7, 8]. In this work we 
show that C32-siRNA polyplexes are effective in knocking down GFP expression in 
HeLa cells. We also demonstrate that the electrostatic peptide and peptide-PEG coatings 
that we developed for C32-DNA nanovectors previously may be applied to siRNA 
complexes. When compared to C32-DNA vectors, C32-siRNA shares similar functional 
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properties. Given the efficient and specific delivery achieved with electrostatically coated 
C32-DNA vectors, we anticipate that siRNA polyplexes may achieve gene knockdown 
with similar efficiency and specificity. By following the path for characterization and 
development that we established with electrostatically coated C32-DNA vectors in vivo, 
these materials have the potential to yield promising new therapies. 
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Chapter 7: Conclusions and Future Directions 
7.1 Protease-Activated Self-Assembly In-vivo 
In Chapter 2 we demonstrated a proof-of-principle design for assembling 
nanoparticles into higher order structures with emergent function upon activation by 
proteases in vitro. This design strategy could be used to enhance signal contrast, increase 
accumulation, or activate a therapeutic function from nanoparticles in tumors. Optimizing 
protease-activated self-assembling nanoparticles to function in vivo is a natural next step. 
Special design criteria should be considered for in vivo development. For intravenous 
tumor delivery, particles should possess the ability to avoid RES clearance and have long 
blood residence times. While the design of the cleavable PEG layer in this system assists 
in this task, care must also be taken to ensure that the size, charge, and hydrophobicity of 
the core nanoparticle minimizes the adsorption of blood opsonins. Recently, our group 
developed a long-circulating iron-oxide nanoworm, which has a shape and coating that 
allows blood half lives on the order of 12 hrs or more. These nanoworms could serve as a 
good starting material for in vivo use.  
Intravenously injected nanoparticles have ready access to the vessels of tumors, but 
larger size particles have limited access to the extravascular space. For applications in 
which extravasation is required, nanoparticle size should be minimized so that they 
diffuse beyond the vascular borders in a reasonable time. The assembly of nanoparticles 
near or within tumor vessels is a more suitable approach for nanoparticles that are greater 
than 10 nm because of transport limitations. One promising strategy for protease-
activated nanoparticle assembly in vivo may be to design particles that are activated by 
 142 
factors in the clotting cascade. Recently, our group designed peptide coated nanoparticles 
that are able to bind fibrin on tumor vessels and induce local clotting. By integrating 
thrombin-activated particles into this tumor-specific clotting system, it may be possible to 
assemble structures within these vessels that possess emergent signaling or therapeutic 
properties. 
 
7.2 Tumor-Responsive PEG Coatings 
In this work we have demonstrated that protease cleavable PEG coatings can veil 
and unveil nanoparticle-nanoparticle and nanoparticle-cell interactions. We showed that 
these coatings improve nanoparticle delivery to tumors and that they are unveiled in the 
tumor. While Chapter 3 focused on the veiling and unveiling of cationic cell internalizing 
domains, cleavable PEG coatings could be used to veil a myriad of other interactions 
between cells and particles. One promising approach may be to transiently veil domains 
that agonize or antagonize proteins on a cell surface. This strategy could be applied to 
particles veiling domains that alter cell proliferation, differentiation, activation, or 
apoptosis within the tumor. For example, it may be possible to manipulate the cytokine 
networks in the tumor microenvironment to promote anti-tumor immunity through the 
delivery of particles that veil and unveil CD40 ligand, which agonizes and activates 
dendritic cells. Though we demonstrated the veiling and unveiling of ligands on a 
nanoparticle surface by proteases, a host of other tumor-relevant activators and cleavable 
linkers such as glycase, lipase, or pH labile bonds could be used to remove PEG coatings. 
Finally, while we demonstrated this strategy on iron-oxide nanoparticles and polymeric 
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gene delivery vectors, these coatings could be adapted to a host of other nanomaterials 
used for imaging or therapy.  
7.3 Electrostatic Peptide-PEG Coatings for Gene Delivery 
Nanovectors 
In Chapter 4 we applied protease cleavable PEG coatings to cationic gene delivery 
nanovectors using a simple electrostatically adsorbed poly (glutamic acid) peptide. We 
found that this coating effectively veiled and unveiled gene delivery function in vitro. 
However preliminary experiments in vivo showed that both the uncoated and cleavable 
PEG coated nanoparticles had relatively short circulation times, ~5 min half-life. We 
found a substantial amount of fluorophore labeled DNA present in the bladder of animals 
shortly after injection of both coated and uncoated vectors. This rapid clearance suggests 
that these complexes degrade relatively quickly in the blood.  
One important next step for this work is to develop more stable gene delivery 
complexes that do not degrade and clear from the blood. The polymer used in this work, 
C32-117, is composed of bonds that degrade quickly at pH 7. This degradation may be 
responsible for the rapid clearance that we see. A non-degradable polymer such as PEI 
could be used to increase the stability of the core complex in the system. Additionally 
peptide-PEG coatings could be covalently coupled to the terminal groups of the 
condensing polymer, instead of electrostatic adsorption, to ensure that the coating 
remains intact in the blood. Such modification should provide increased circulation time 
and enhanced accumulation of gene delivery probes in the tumor. 
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7.4 Electrostatic Coatings for DNA Delivery 
The organ specific gene delivery achieved in Chapter 5 using electrostatically 
adsorbed peptide coatings provides a promising tool that could be applied to the 
treatment of certain cancers and other diseases. While we demonstrated the stable 
delivery of the Factor IX gene to the liver, these coated vectors could be used to deliver 
any gene of interest. For example this technique could be use to transfect anti-HCV genes 
in the liver to halt the replication of HCV and reduce end-stage complications of this 
disease such as fibrosis and hepatocellular carcinoma. 
 Electrostatic coatings that tune the delivery of genes to the marrow could be 
useful for targeting cancers such as leukemia’s or bone metastases. A natural next step 
for this work is to apply these materials in animal models to test their ability to transfect 
cancer cells. Also, a significant proportion of cells that are transfected by vectors coated 
in poly-E-cat peptides are monocytes of the marrow. It may be possible to transfect these 
cells and have them migrate to peripheral tissues or tumors to express a protein of 
interest. This could be a promising approach for delivering therapeutic genes to hard to 
reach areas such as the brain. 
Because we see a substantial difference in the function of poly-E coatings when 
amino acids of a particular sequence are inserted in the peptide terminus, further 
examination of the parameters that mediate these changes in targeting in vivo is an 
important next step for this work. The length, ionic character, hydrophobicity, density, 
and poly (glutamic acid) chain length are all variables that could be tested to identify 
those peptide sequences that achieve highly specific delivery to certain organs. By 
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screening these peptides it may also be possible to uncover sequences that target other 
tissues including lung, tumor, or brain. 
7.5 Electrostatic Coating for siRNA Delivery 
In chapter 6 we use C32-117 and electrostatic peptide and peptide-PEG coatings to 
effectively knock down GFP expression in HeLa GFP cells. While we demonstrated that 
C32-siRNA nanoparticles function in similar ways to C32-DNA nanoparticles in vitro, 
we did not test these coatings in animal models. A natural next step for this work will be 
to test if C32-siRNA nanoparticles coated in poly-E and poly-E-cat coatings deliver 
siRNA to the liver and marrow of mice in an efficient and specific manner. To do so, 
genes need to be identified that would allow for knockdown in liver or marrow to be 
assessed. Because the delivery of partially coated C32 nanoparticles is localized to 
sinusoidal endothelial cells, an ideal target gene should be expressed by these cells and be 
measurable in the blood for easy assessment (e.g. Factor VIII). To assess marrow 
delivery, siRNAs that target surface markers on monocytes could be delivered and 
marrow-isolated monocytes could be analyzed to test knockdown with flow cytometry. 
While there is substantial work that needs to be done to develop these materials for 
clinical use, a clear path for the in vivo characterization and development of these vectors 
has been laid by the work presented here. 
